Exercise-Induced Acute Renal Failure
Acute Renal Failure with Severe Loin Pain and Patchy Renal Ischemia After Anaerobic Exercise
Exercise-Induced Acute Renal Failure

Acute Renal Failure with Severe Loin Pain and Patchy Renal Ischemia After Anaerobic Exercise

With 76 Figures, Including 5 in Color
There are two types of exercise-related acute renal failure, one of which is myoglobinuric acute renal failure. In myoglobinuric acute renal failure, strenuous exercise such as marathon running or mountain climbing causes marked rhabdomyolysis, resulting in myoglobinuria. However, Acute renal failure with severe Loin pain and Patchy renal ischemia after anaerobic Exercise (ALPE), which we describe in this text, differs from myoglobinuric acute renal failure. The first patient known to have ALPE attended an emergency outpatient unit one night with severe loin pain. Under a tentative diagnosis of ureteral stone, the patient underwent intravenous pyelography (IVP). However, there was no ureteral stone. Several hours later, a plain computed tomography (CT) scan revealed wedge-shaped contrast enhancement in the kidney. In 1981, we initially reported this finding as “patchy renal vasoconstriction in man” [1]. Thereafter, we encountered several patients with acute renal failure and some common characteristics. These were severe loin pain after exercise and wedge-shaped contrast enhancement in the kidney on CT, but with no marked increases in serum creatine phosphokinase (CPK)/myoglobin levels, as described for the first patient. In 1982, we reported this condition as a new acute renal failure syndrome [2]. A subsequent study showed that this type of acute renal failure frequently developed in patients with renal hypouricemia [3]. As this disorder is associated with anaerobic exercise, it is called acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise (ALPE) [4].

In this text, we emphasize that ALPE should always be considered in patients who complain of severe loin pain and nausea after sprinting in an athletics meeting, and while ALPE frequently develops in patients with renal hypouricemia, it also develops in those without it.

We would like specialists in emergency care, general practitioners, nephrologists, pediatricians, school physicians, and sports physicians to read this text.
## Contents

Preface ................................................................. V

Color Plates ......................................................... XI

Chapter 1 Exercise-Related Acute Renal Failure ............... 1
  1 Description of Exercise-Related Acute Renal Failure .......... 1
  2 Myoglobinuric/Non-Myoglobinuric Acute Renal Failure ........ 1

Chapter 2 Exercise-Induced Acute Renal Failure (ALPE) ...... 3
  1 The First Patient in Whom Wedge-Shaped Patchy Renal Ischemia was Demonstrated ............................................................. 3
  2 Our Series in the Initial Phase .......................................... 3

Chapter 3 Wedge-Shaped Patchy Renal Ischemia ............... 9
  1 Visualization of Residual Contrast Medium on Delayed CT in Relation to the Interval from the Administration of Contrast Medium (Assessment of Regional Kidney Function) ..................... 9
  2 Interpretation of Wedge-Shaped Renal Lesions ...................... 11
  3 Administration of Contrast Medium in the Presence of Acute Renal Failure .............................................................. 13
  4 Visualization of Wedge-Shaped Lesions by Bone Scan with MDP and MRI ............................................................ 14

Chapter 4 Definition of Exercise-Induced Acute Renal Failure (ALPE) .............................................. 17
  1 Criteria for Typical ALPE ............................................. 17
  2 Nontypical Cases ....................................................... 19

Chapter 5 Our Series (22 Patients) .............................. 21
  1 Patient Characteristics .............................................. 21
Chapter 6 Summary of 155 Cases Collected from the Literature

1 Background
2 Findings and Laboratory Data on the First Visit
3 Renal Hypouricemia
4 Imaging Findings (Wedge-Shaped Patchy Renal Ischemia)
5 Kidney Biopsy
6 Relapse

Chapter 7 Exercise

1 Type of Exercise
2 Anaerobic Exercise
3 Involvement of Type II Muscle Fibers

Chapter 8 Loin Pain

1 Timing of Onset and Duration
2 Sites and Features of Pain
3 Mechanism Involved in Pain

Chapter 9 Renal Hypouricemia

1 Serum Creatinine and Uric Acid Levels
2 Comparison of Patients With and Without Renal Hypouricemia
3 Reasons for a High Incidence of ALPE in Patients with Renal Hypouricemia
4 Reason why Patients with Renal Hypouricemia Frequently Develop ALPE, and its Mechanism

Chapter 10 Gene Analysis of Uric Acid Transporter (URAT1)

1 URAT1 Gene Analysis in Patients with Renal Hypouricemia who Developed ALPE

Chapter 11 Risk Factors Other than Renal Hypouricemia

1 Exercise in the Presence of a Cold
2 Administration of Antipyretic Analgesics Before Exercise
3 Exercise in the Presence of Dehydration

Chapter 12 Etiology/Pathogenesis

1 Hypothesis About the Development of Exercise-Induced Acute Renal Failure (ALPE)
2 Investigation of Serum-Specific Markers (SDS–PAGE, Proteomics) ....... 67
3 Investigation of Oxidative Stress Markers ........................................ 70
4 Exercise Load Tests ........................................................................... 70
5 Preparation of Wedge-Shaped Patchy Renal Ischemia in an Animal Experiment .......................................................... 73
6 Verification of Hypotheses .............................................................. 73
   6.1 Does ALPE develop via the release of a renal vasoconstricting substance by type II muscle fibers? .................. 73
   6.2 Involvement of active oxygen and various vasoactive substances ................................................................. 74
   6.3 Why does vascular spasm persist for a long period? ............... 74

Chapter 13 Diagnosis ................................................................. 75
1 Initially Suspected Disorders .......................................................... 75
2 Diagnosis of ALPE .......................................................................... 75
3 Differentiation of ALPE from Myoglobinuric Acute Renal Failure ...... 75
4 Necessity of Visualizing Wedge-Shaped Patchy Renal Ischemia ......... 79

Chapter 14 Treatment ................................................................. 81
1 Treatment ..................................................................................... 81
2 Precautions .................................................................................. 81

Chapter 15 Disease Course and Prognosis ....................................... 83
1 Interval Required Until Improvement in Kidney Function ................ 83
2 Prognosis: Patients Undergoing Hemodialysis ................................. 83

Chapter 16 Prevention ..................................................................... 85
1 Preventive Methods ...................................................................... 85
2 Precautions for Elementary and Junior/Senior High Schools ........... 85

Chapter 17 Conclusions ................................................................. 87

Postscript ....................................................................................... 89

Acknowledgments .......................................................................... 91

Brief History of the Author ............................................................. 93

References ..................................................................................... 95

Index ............................................................................................. 105
Fig. 4. Kidney biopsy. The findings suggested acute tubular necrosis (p. 4).

Fig. 5. The reason why we considered that wedge-shaped contrast enhancement reflected a vascular lesion. We infused microspheres in the rat heart, and performed glomerular supervital staining with Alcian blue. In this rat, renal infarction was detected. This was the basis of the hypothesis that wedge-shaped lesions are related to vasoconstriction (p. 4).

Fig. 6. SDS–PAGE in normal controls and in patients with myoglobinuric acute renal failure, ALPE, or acute renal failure related to other etiologies. There were no bands which were specific to ALPE. ARF, acute renal failure (p. 68).
Fig. 64. Proteomic analysis with a SELDI-TOF-MS. In single marker analysis (left), the relative intensity of the 3.5 KDa peptide was high in the ALPE group. In the hierarchical clustering analysis with marker candidates, the heat map in the ALPE group differed from those in the myoglobinuric acute renal failure and normal groups (p. 69).

Fig. 72. Wedge-shaped contrast enhancement after the administration of vasopressin in an animal model (p. 73)
Chapter 1
Exercise-Related Acute Renal Failure

1 Description of Exercise-Related Acute Renal Failure

In 1910, Meyer-Betz reported the first published case of acute renal failure with muscular pain, weakness, and dark urine after intense exercise [5]. In 1960, Howeustine reported that this type of acute renal failure was exercise-related myoglobinuric [6]. However, at this time, it was impossible to distinguish hemoglobin from myoglobin, and this type of acute renal failure was considered to be a type of heat stroke. However, in 1970, Jackson [7] reported that this disorder was exercise-related renal failure and muscle damage, and this publication led to a gradual increase in research interest in myoglobinuric acute renal failure. In 1972, Hamilton et al. [8] and Knochel [9], respectively, reported that similar cases were exertional rhabdomyolysis. Matsumoto et al. [10] first reported this disorder in Japan in 1976.

In all case reports, the levels of creatine phosphokinase (CPK) were markedly increased to about 70,000 mU/ml or more [11]. Furthermore, this disorder frequently develops in people who are not accustomed to exercise, and is therefore called white-collar rhabdomyolysis [12], which indicates myoglobin-related acute renal failure.

In 1982, we classified exercise-related acute renal failure into two types: myoglobinuric acute renal failure, as had previously been reported, and non-myoglobin-related acute renal failure (exercise-induced acute renal failure). In 2002, the latter was named ALPE (Acute renal failure with severe Loin pain and Patchy renal ischemia after anaerobic Exercise) [4]. The term ‘acute kidney injury’ (AKI) has recently been proposed as a pathophysiological more correct alternative to the term acute renal failure. Therefore, exercise-induced acute renal failure in this book may be replaced by exercise-induced acute kidney injury.

2 Myoglobinuric/Non-Myoglobinuric Acute Renal Failure

Exercise-related acute renal failure is classified into two types (Table 1). One type is myoglobinuric acute renal failure, in which strenuous exercise over a long period of time, such as marathon running and mountain climbing, causes severe rhabdomyolysis with myoglobinuria. The clinical course of myoglobinuric acute renal failure in one of our patients is shown in Fig. 1. The patient was a male student who developed this disorder during a Shorinji Kenpo (one of the combative sports with technique of bare hand self defense) training camp. His CPK level had increased to approximately 30,000 mU/ml, and dark urine and muscular pain in the upper and lower limbs were
Exercise-Induced Acute Renal Failure

Table 1. Exercise-related acute renal failure

| Massive rhabdomyolysis—myoglobinuric acute renal failure due to marathon, mountain climbing, |
| Minimum rhabdomyolysis—non-myoglobinuric acute renal failure due to exercise-induced acute |
| renal failure—ALPE (acute renal failure with severe loin pain and patchy renal ischemia after |
| anaerobic exercise) after sprint, short track event such as 200-m race, etc. |

Fig. 1. Acute tubular necrosis (acute renal failure) due to myoglobinuria (rhabdomyolysis) after Shorinji Kenpo

noted. Furthermore, this patient showed a typical electrolyte imbalance in the presence of rhabdomyolysis, and required hemodialysis because of oliguria. This case is typical of exercise-related myoglobinuric acute renal failure.

The other type is non-myoglobinuric acute renal failure, in which intense exercise over a short period of time, such as sprinting, causes minimal rhabdomyolysis without myoglobinuria, i.e., acute renal failure syndrome with severe loin pain and patchy renal vasoconstriction [2]. A recent study showed that anaerobic exercise caused this syndrome, and proposed that “Acute renal failure with severe Loin pain and Patchy renal ischemia after anaerobic Exercise (ALPE) (exercise-induced acute renal failure)” was a new type of acute renal failure syndrome [4].
Chapter 2
Exercise-Induced Acute Renal Failure (ALPE)

1 The First Patient in Whom Wedge-Shaped Patchy Renal Ischemia was Demonstrated

The first patient to be recognized as having this condition was a 29-year-old man [1].
On August 20, 1979, he attended an emergency outpatient unit at night with severe
loin pain. His serum creatinine level was slightly increased (1.6 mg/dl). Under a tenta-
tive diagnosis of ureteral stone, an intravenous pyelography (IVP) was performed.
However, there was no stone. Plain computed tomography (CT) 22 h after the admin-
istration of a contrast medium (delayed CT: plain CT several hours or days after the
administration of a contrast medium) (Fig. 2) showed patchy wedge-shaped contrast
enhancement in the bilateral kidneys (the first image in a human). This persisted for
48 h after administration of the medium (Fig. 3) [1]. A kidney biopsy 2 weeks after
onset suggested acute tubular necrosis (Fig. 4). At the same time, we were conducting
an experiment involving an infusion of microspheres into a rat heart and glomerular
supervital staining with Alcian blue, and we found some wedge-shaped lesions. As
this finding suggested renal infarction (Fig. 5), we speculated that the wedge-shaped
contrast enhancement in our patient was associated with a vascular lesion
(vasoconstriction).

This case report was published in Nephron in 1981 as evidence for patchy renal
vasoconstriction in humans [1].

2 Our Series in the Initial Phase

A 28-year-old man (Patient 1). This patient complained of a mild headache which
persisted for 2 days, and took a mixed preparation consisting of aminopyrine at
108 mg and phenacetin at 400 mg at 0900 hours on October 14, 1979. After 1 h, he ran
a 200-m race in an athletics meeting. Bilateral loin pain then occurred. After 8 h, the
pain became severe and he attended an emergency outpatient unit during the night.
Two days after onset, his serum creatinine level was 2.8 mg/dl, his serum myoglobin
level was normal, and his creatine phosphokinase (CPK) level was slightly increased.
Three days after onset, a new type of acute renal failure was suspected, and a CT scan
of his kidneys was performed 2, 24, 48, and 72 h after the intravenous administration
Exercise-Induced Acute Renal Failure

**Fig. 2.** Plain computed tomography (CT) 22 h after the administration of contrast medium. Wedge-shaped contrast enhancement was observed in the bilateral kidneys (From [1], with permission)

**Fig. 3.** Slight wedge-shaped contrast enhancement (arrows) was observed 48 h after the administration of contrast medium (bottom)

**Fig. 4.** Kidney biopsy. The findings suggested acute tubular necrosis

**Fig. 5.** The reason why we considered that wedge-shaped contrast enhancement reflected a vascular lesion. We infused microspheres in the rat heart, and performed glomerular supervital staining with Alcian blue. In this rat, renal infarction was detected. This was the basis of the hypothesis that wedge-shaped lesions are related to vasoconstriction
of a contrast medium (40 ml of 67% sodium iothalamate). The CT scan 48 h after administration of the medium (Fig. 6) showed diffuse to patchy contrast enhancement, and this finding persisted until 72 h after the contrast administration. The patient’s serum creatinine level was 7.1 mg/dl 4 days after onset. However, oliguria was not observed, and conservative therapy reduced the level of serum creatinine. A kidney biopsy 36 days after onset suggested the regeneration of acute tubular necrosis. The loin pain persisted for 4 days.

A 24-year-old man (Patient 2). This patient participated in a 200-m swimming race at 1600 hours on August 9, 1980. Immediately after this exercise, headache and nausea developed. On August 10, severe bilateral loin pain occurred at 0100 hours (9 hours after the race), and he attended an emergency outpatient unit. Pentazocine hydrochloride was given by injection. Urinalysis showed no abnormalities, and the patient was negative for fecal occult blood. His serum amylase level was normal. On August 11, IVP suggested kidney hypofunction, but there was no stone in the urinary tract. A plain CT scan of the kidneys after 24 h showed bilateral patchy contrast enhancement (Fig. 7). A subsequent routine contrast-enhanced CT scan showed diffuse contrast enhancement immediately after the administration of the contrast medium, and bilateral wedge-shaped contrast enhancement 24 h later. The patient’s urine volume was normal, and the loin pain persisted for 4 days.

A 24-year-old man (Patient 3). This patient had flu-like symptoms, and took a mixed preparation consisting of bucitin at 120 mg and aspirin at 240 mg. After 15 h, he participated in a 200-m race in an athletics meeting (October 10, 1980). After 6 h, he attended our hospital with nausea and bilateral loin pain. The severe pain, which made it impossible for him to drive a car, persisted for 2 days. His serum creatinine and urinary protein levels were 2.4 mg/dl and 2+, respectively, 4 days after onset. The patient was negative for urinary occult blood, and his urinary sodium level was 99 mEq/l. On the same day, drip infusion pyelography (DIP) revealed no ureteral

Fig. 6. Delayed CT 48 h after the administration of contrast medium. The serum creatinine level was high (5.5 mg/dl), and the contrast-enhanced areas were more extensive than those in Fig. 2 (serum creatinine 1.6 mg/dl). Patchy contrast enhancement changed to diffuse contrast enhancement.
stone, and kidney hypofunction was suggested. A CT of the kidney 6h after the administration of a contrast medium showed patchy contrast enhancement in the kidney. In order to assess regional kidney function, dynamic CT was performed repeatedly within 3 min after bolus administration of the contrast medium (40 ml of 67% sodium iothalamate injected within 15 s through the anterior elbow vein) to investigate the process of contrast medium excretion [13]. The results are shown in Fig. 8 and in the analytical Fig. 14. Thirteen days after onset, the patient’s serum creatinine level returned to 1.2 mg/dl.
A 35-year-old man, policeman. This patient took a single dose of aminopyrine at 375 mg, aminopropionic acid at 500 mg, and amoxicillin at 125 mg after pharyngeal pain had persisted for 5 days. After 2 h, nausea, vomiting, and loin pain occurred. On November 28, 1980, he attended an emergency outpatient unit at midnight with severe pain. Pentazocine hydrochloride was given by injection. On November 29, IVP was performed at 0300 hours after a tentative diagnosis of ureteral stone. However, there was no stone, and nephrograms were repeated. After 1 h, a CT scan of the kidney showed diffuse contrast enhancement (Fig. 9). However, plain CT after 21 h (delayed CT) showed patchy contrast enhancement, and this persisted for 45 h (Fig. 10). Furthermore, a CT scan of the kidney 1 and 1.5 h after oral administration

**Fig. 9.** Delayed CT 1 h after the administration of contrast medium (serum creatinine 3.3 mg/dl)

**Fig. 10.** Delayed CT 45 h after the administration of contrast medium
of an angiotensin-converting enzyme inhibitor (SQ 14225) at 125 mg did not reveal any changes (Fig. 11). The administration of SQ 14225 did not influence the patchy contrast enhancement, suggesting that SQ 14225 had not improved creatinine clearance. The patient’s serum creatinine level was 2.8 mg/dl before IVP on November 28, and reached a maximum (3.6 mg/dl) 2 days after IVP, but gradually decreased to 2.1 mg/dl 4 days after IVP. Loin pain persisted for 5 days. His lactic acid dehydrogenase (LDH) level, serum myoglobin level, and urine volume were normal. Dark urine was not noted. His CPK level was slightly increased. Urinalysis showed that his urinary protein level was 1+, and was negative for occult blood.

In a text book on acute renal failure, published in 1982 [2], the four patients described above and the first ever patient were reported to have a new type of acute renal failure syndrome.
Chapter 3
Wedge-Shaped Patchy Renal Ischemia

1 Visualization of Residual Contrast Medium on Delayed CT in Relation to the Interval from the Administration of Contrast Medium (Assessment of Regional Kidney Function)

Contrast medium is filtered from glomeruli and excreted by the kidney. Owing to the differences in kidney function in local areas, a patchy lesion is visualized, not a diffuse lesion. We performed dynamic computed tomography (CT) in order to examine changes in the early phase after the administration of contrast medium (cortical phase, after 20–30 s). In areas with severe renal ischemia, contrast enhancement was less marked, and there was minimal cortical enhancement (the uptake of contrast medium was low at 3 min). However, in areas with mild renal ischemia, stronger contrast enhancement was observed. Delayed CT of a few hours and 1–2 days after the administration of contrast medium showed gradual wedge-shaped contrast enhancement in areas with severe renal ischemia (Fig. 12). However, in areas with mild renal ischemia, contrast medium had been excreted, and there was no contrast enhancement. The sites of contrast enhancement on CT were reversed a few hours and 1–2 days after the administration of contrast medium compared with those 3 min after administration [4] (Fig. 12). Wedge-shaped contrast enhancement was clearly observed on delayed CT 3 h and 1–2 days after the administration of contrast medium.

The mechanism by which wedge-shaped lesions were enhanced may involve renal vasoconstriction or tubular obstruction, as shown in Fig. 13. However, as bilateral multiple wedge-shaped lesions were detected, we considered that vasoconstriction was involved because vasoconstriction at the interlobar/arcuate artery level (Fig. 13-1) may be more probable than tubular obstruction in the papillary region (Fig. 13-2). Briefly, a serial increase in the level of contrast medium in severe lesions is similar to the delayed appearance time and hyperconcentration shown in a later film on the stenosed side of the kidney by rapid intravenous pyelography in a patient with renal artery stenosis. Contrast enhancement persisted for a few days, possibly because renal vasoconstriction extended the reduced glomerular filtration rate (GFR) in the area of severe renal ischemia. The small volume of contrast medium which filtered through
Exercise-Induced Acute Renal Failure
during this period may have been concentrated in the renal tubules, resulting in hyperconcentration. However, if tubular obstruction is involved in the mechanism, multiple lesions obstructing several collecting tubules simultaneously must develop in the bilateral kidneys. No study has reported patchy wedge-shaped contrast enhancement even in patients with tubular obstruction due to uric acid crystals (acute uric acid nephropathy).

Fig. 12. Relationship between the interval after the administration of contrast medium and wedge-shaped contrast enhancement (From [4], with permission)

Fig. 13. Mechanism involved in wedge-shaped lesions
2 Interpretation of Wedge-Shaped Renal Lesions

The area of wedge-shaped contrast enhancement increased with the increase in serum creatinine level. When the serum creatinine level exceeded 5 or 6 mg/dl, diffuse contrast enhancement involved the entire kidney. However, even in patients with diffuse contrast enhancement, delayed CT confirmed patchy wedge-shaped contrast enhancement again when the serum creatinine level decreased to 1.2–3.5 mg/dl in the recovery phase (refer to Patient 2 in Fig. 59, Chap. 10, Sect. 1). This finding in the recovery phase cannot be explained by tubular obstruction.

In order to compare kidney function between the areas where contrast persisted and those where contrast did not persist, we performed additional dynamic CT in a patient with wedge-shaped contrast enhancement [14] (Fig. 14, Patient 3).

We designed a method of evaluating regional kidney function [13]. First, 40 ml contrast medium was infused into the forearm vein within 15 s, and dynamic CT was performed at the same slice level at specific intervals. We confirmed the gradual transfer of contrast medium from the cortex to the medulla. We established the region of interest in the cortex/medulla, and serially investigated changes in the CT attenuation value in that region to evaluate kidney function (Figs. 15 and 16) [13]. The interval before the cortical curve crossed the medullary curve was correlated with glomerular filtration rate to some degree. In the area where contrast did not persist, the interval before the cortex curve crossed the medulla curve was nearly normal (Fig. 16), as shown in Fig. 14. However, in the area where contrast persisted on delayed CT, cortical/medullary contrast enhancement was less marked, and similar curves were noted. The kidney function was almost normal in the area where contrast did not persist, but was reduced in the area where contrast persisted [14]. In addition, the area where contrast did not persist on delayed CT showed no renal infarction.

Fig. 14. Analysis of cortical and medullary curves by dynamic CT (comparison of function between the areas where contrast persisted and the areas where contrast did not persist) (From [14], with permission)
Subsequently, we examined whether it is only patients with exercise-induced acute renal failure (ALPE) who show wedge-shaped contrast enhancement [15–18]. We performed delayed CT on a patient with ALPE and a patient with myoglobinuric acute renal failure (due to a malignant syndrome) when their serum creatinine levels were 3.0 and 1.5 mg/dl, and compared the results. Wedge-shaped contrast enhancement was observed only in the patient with ALPE (Patient 19), and not in the patient with myoglobinuric acute renal failure. Diffuse contrast enhancement was noted (serum creatinine level, 3 mg/dl) (Fig. 17).
3 Administration of Contrast Medium in the Presence of Acute Renal Failure

After confirming the absence of dehydration, we carefully administered contrast medium at a reduced dose (40 ml) to patients with acute renal failure. We have not encountered any patient with an exacerbation of acute renal failure as a result of this treatment. Previous studies have indicated the safety of contrast medium in patients with acute renal failure, since it frequently induces overhydration, and thus differs from chronic renal failure [19,20]. However, another study reported that the administration of 100 ml contrast medium slightly prolonged the duration of oliguria [18]. When physicians hesitate to administer contrast medium in the presence of acute renal failure, a bone scan with \(^{99m}\)Tc-methylene diphosphonate (MDP), magnetic resonance imaging (MRI) with gadolinium–diethylene triaminepentaacetic acid (Gd–DTPA), and ultrasonography with Levovist can be performed. These procedures facilitate the detection of patchy lesions in some patients, although they are less sensitive than delayed CT.
4 Visualization of Wedge-Shaped Lesions by Bone Scan with MDP and MRI

Based on the finding that a bone scan with MDP showed muscular accumulation when rhabdomyolysis was marked [21], we performed this procedure on a patient. There was no muscular accumulation of MDP, but patchy accumulation was observed in the kidney, as shown in Fig. 18. This patient (Patient 5) was a physician in our department who had attended the Emergency Outpatient Unit for abdominal pain after skiing. His serum creatinine level was 2.0 mg/dl, and self-diagnosis suggested acute pancreatitis. However, 17 h after the administration of contrast medium, CT showed typical multiple wedge-shaped contrast-enhanced areas (Fig. 19). A bone scan with MDP accumulating in the ischemic site revealed a patchy accumulation of isotope in the renal ischemic site, which was consistent with the CT finding described above, and not in the muscle [22] (this photograph was printed on the cover of *Nephron*, see Fig. 20). However, in a bone scan with MDP, thick kidneys are visualized as 2-dimensional images, and this procedure is less sensitive in detecting patchy lesions than a CT scan. The course of this patient’s condition is shown in Fig. 21. Some patchy lesions can be visualized by MRI in another patient (Fig. 22).

Fig. 18. Bone scan images with methylene diphosphonate (MDP). Patchy accumulation was observed in the kidney (From [22], with permission)
Fig. 19. Delayed CT 17 h after the administration of contrast medium to the patient in Fig. 18. Wedge-shaped contrast enhancement was observed in the bilateral kidneys (From [22], with permission)

Fig. 20. MDP bone scan images in the patient in Fig. 18 were published on the cover of *Nephron* (From [22], with permission)
Exercise-Induced Acute Renal Failure

CT scan    99mTc-MDP  GFR 100.6 (ml/min) RPF 552.2 (ml/min) FF 0.18
Abdominal pain
Loin pain
Nausea
CT scan    4/14

Fig. 21. Clinical course of Patient 5 (presented in Figs. 18 and 19)

Fig. 22. Magnetic resonance imaging (MRI) without contrast medium showed wedge-shaped contrast enhancement in some patients (Patient 16; TR3600, TE138)
Chapter 4
Definition of Exercise-Induced Acute Renal Failure (ALPE)

1 Criteria for Typical ALPE

The criteria used in a diagnosis of ALPE are listed below.

1. Recent intense (anaerobic) exercise such as a short-distance sprint.
2. Mild rhabdomyolysis (which differs from that in myoglobinuric acute renal failure patients), and serum levels of creatine phosphokinase (CPK) and myoglobin, which are normal or slightly increased (less than 7 times the reference value for serum myoglobin, and less than 9 times the reference value for CPK).
3. Severe loin pain several hours after exercise.
4. Wedge-shaped contrast enhancement on plain CT from a few hours to 72h after the administration of a contrast medium (however, delayed CT after administration of the contrast medium is not essential to making a diagnosis).

The selection criteria for data collection are shown in Table 2. Using these criteria, we reviewed the literature to investigate whether similar cases were described. One of the cases reported by Jackson in 1970 met the criteria [7]. This patient was an English soldier. Acute renal failure developed with vomiting and loin pain after a 200-m sprint and a 100-m race (Fig. 23). Severe bilateral loin pain persisted for 10 days. Jackson reported this patient as having myoglobinuric acute renal failure. However, he may have had ALPE. In Japan, in the case of a patient who developed muscular pain involving the right back to lumbar area and right lateral dorsal pain after a 100-m race, with a slight increase in CPK, Ueda et al. [23] reported that the patient had myoglobinuric acute renal failure. However, this patient may also have had ALPE.

In relation to the term “exercise-induced acute renal failure,” this disorder was expressed as “loin pain and acute renal failure after exercise (athletics meeting)” in 1981 [24] (Fig. 24). Later, however, Nishimura and Takahara [25], Ishii et al. [26], and Nakamura et al. [27] named this disorder “exercise-induced acute renal failure.” Since then, this term has commonly been used [3].
Exercise-Induced Acute Renal Failure

Table 2. Exercise-induced acute renal failure (ALPE)

Selection criteria
1. Intense (anaerobic) exercise such as a short-distance sprint
2. CPK less than 9 times and serum myoglobin less than 7 times the reference values
3. Acute renal failure with severe loin pain

Patient with (1), (2), and (3)

Total number of patients 155

CPK, creatine phosphokinase

Fig. 23. A copy of the sentences suggesting ALPE in Jackson’s study (From [7], with permission)

Fig. 24. A copy of the description of ALPE published in Igaku-No-Ayumi (J Clin Exp Med). “Topics: loin pain and acute renal failure after exercise (athletics meeting). When patients with this new syndrome come to an emergency room complaining of loin pain, they are often misdiagnosed as having radiolucent urolithiasis. When a patient complains of severe loin pain after unaccustomed violent exercise at an athletics meeting or during summer bathing, in particular after taking a nonsteroidal anti-inflammatory drug (NSAID) for flu-like symptoms, this new syndrome should be suspected. In addition, the patient’s serum creatinine level must be measured.” (From [24], with permission)
2 Nontypical Cases

Some patients have nontypical ALPE. Some do not clearly remember having exercised [1,28,29], and others do not complain of loin pain [30,31]. In addition, others concurrently develop myoglobinuric acute renal failure and exercise-induced acute renal failure (ALPE), and show the characteristics of both disorders [32,33].

In the first patient and the fourth patient in our initial series (p. 7), the association of ALPE with anaerobic exercise had not yet been recognized, and their medical histories may have been insufficient, or the patients may not have reported intense exercise over a short duration. In acute renal failure patients with loin pain of unknown etiology, the presence or absence of anaerobic exercise should always be ascertained when taking their medical history. Erley et al. [28] did not comment on exercise in their study. However, when Sato et al. inquired about exercise in 1998 [34], Erley et al. reported that the patient had undertaken exercise.

In this study, these patients were regarded as nontypical cases, and were excluded from our series/data.
Chapter 5
Our Series (22 Patients)

1 Patient Characteristics

We have encountered a total of 22 patients with exercise-induced acute renal failure [4], and our clinical findings are summarized in Table 3. In most patients their creatine phosphokinase (CPK) and serum myoglobin levels were normal or slightly increased. In no patient were these levels higher than 10–20 times the reference values, which is different from patients with myoglobinuric acute renal failure. The type of exercise involved was anaerobic exercise requiring instant power over a short duration, such as short-distance running (sprinting), a swimming race, or weightlifting. In particular, 50% of the patients developed acute renal failure after running at full speed (sprinting) in an athletics meeting, and this disorder was considered to be post-athletics meeting or post-anaerobic exercise acute renal failure. In 4 of the 22 patients, renal hypouricemia was observed.

Patient 1: a 28-year-old man
This patient was the first case in our series in which acute renal failure developed after an athletics meeting. After he had participated in a 200-m race, loin pain occurred, leading to acute renal failure. Delayed computed tomography (CT) showed diffuse to patchy contrast enhancement. The details are given in Chap. 2, Sect. 2.

Patient 2: a 24-year-old man
Loin pain developed 9 h after a 200-m swimming race, leading to acute renal failure. CT 24 h after intravenous pyelography (IVP) showed patchy contrast enhancement. The details are given in Chap. 2, Sect. 2.

Patient 3: a 24-year-old man
This patient developed exercise-induced acute renal failure (ALPE) after participating in a 200-m race in an athletics meeting on a Health-Sports Day. When delayed CT showed patchy contrast enhancement, dynamic CT was performed in order to evaluate regional kidney function. The details are given in Chap. 2, Sect. 2.

Patient 4: a 27-year-old man
This patient’s serum creatinine level was 3.7 mg/dl, which was higher than the value in the first patient. The area of residual contrast enhancement was also larger
### Table 3. Clinical findings in our 22 patients with exercise-induced acute renal failure (ALPE)

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Prodrome (flu-like symptoms)</th>
<th>Analgesics</th>
<th>Exercise</th>
<th>Loin pain</th>
<th>Duration of pain (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>28</td>
<td>Male</td>
<td>+</td>
<td>+</td>
<td>Athletics meeting 200 m</td>
<td>+++</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>24</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Swimming</td>
<td>+++</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>24</td>
<td>Male</td>
<td>+</td>
<td>+</td>
<td>Athletics meeting 200 m</td>
<td>+++</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>27</td>
<td>Male</td>
<td>–</td>
<td>/</td>
<td>Athletics meeting 200 m × 3</td>
<td>+++</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>Male</td>
<td>+</td>
<td>+</td>
<td>Skiing (2 h)</td>
<td>+++</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>Male</td>
<td>–</td>
<td>+</td>
<td>Weightlifting</td>
<td>++</td>
<td>7</td>
</tr>
<tr>
<td>7</td>
<td>17</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 400 m</td>
<td>+++</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>22</td>
<td>Male</td>
<td>+</td>
<td>+</td>
<td>Athletics meeting 100 m × 2</td>
<td>++</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>24</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 200 m</td>
<td>+++</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>31</td>
<td>Male</td>
<td>+</td>
<td>–</td>
<td>Athletics meeting 100 m × 2</td>
<td>+++</td>
<td>3</td>
</tr>
<tr>
<td>11</td>
<td>33</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 100 m × 2</td>
<td>+</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>34</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Flying a light plane</td>
<td>+++</td>
<td>3</td>
</tr>
<tr>
<td>13</td>
<td>21</td>
<td>Male</td>
<td>/</td>
<td>/</td>
<td>Near drowning</td>
<td>++</td>
<td>/</td>
</tr>
<tr>
<td>14</td>
<td>15</td>
<td>Male</td>
<td>/</td>
<td>/</td>
<td>Baseball</td>
<td>++</td>
<td>/</td>
</tr>
<tr>
<td>15</td>
<td>26</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 100 m × 2</td>
<td>+++</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>19</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Time trial</td>
<td>+++</td>
<td>4</td>
</tr>
<tr>
<td>17</td>
<td>19</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Physical training</td>
<td>+++</td>
<td>7</td>
</tr>
<tr>
<td>18</td>
<td>41</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 150 m × 2</td>
<td>+++</td>
<td>14</td>
</tr>
<tr>
<td>19</td>
<td>39</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Near drowning</td>
<td>+++</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>27</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Baseball (6 h)</td>
<td>++</td>
<td>5</td>
</tr>
<tr>
<td>21</td>
<td>14</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Athletics meeting 400 m × 2</td>
<td>+</td>
<td>9</td>
</tr>
<tr>
<td>22</td>
<td>16</td>
<td>Male</td>
<td>–</td>
<td>–</td>
<td>Badminton</td>
<td>+</td>
<td>7</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>Slight fever</td>
<td>Initial serum creatinine (mg/dl)</td>
<td>Maximum serum creatinine (mg/dl)</td>
<td>Duration of ARF (days)</td>
<td>Renal CT findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>2.8</td>
<td>7.1</td>
<td>20</td>
<td>Diffuse, patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>2.4</td>
<td>2.4</td>
<td>13</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>3.7</td>
<td>3.7</td>
<td>9</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>−</td>
<td>2</td>
<td>2.1</td>
<td>5</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>1.2</td>
<td>1.2</td>
<td>3</td>
<td>Partially patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td>+</td>
<td>7.3</td>
<td>8.1</td>
<td>18</td>
<td>Diffuse to patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>3.9</td>
<td>3.9</td>
<td>12</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>−</td>
<td>1.9</td>
<td>2.1</td>
<td>6</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>/</td>
<td>/</td>
<td>4.2</td>
<td>19</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+++</td>
<td>/</td>
<td>/</td>
<td>5</td>
<td>10</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>2.1</td>
<td>3</td>
<td>6</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>1.5</td>
<td>1.8</td>
<td>7</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>3.7</td>
<td>5.1</td>
<td>19</td>
<td>Diffuse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>1.6</td>
<td>1.6</td>
<td>10</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>2.1</td>
<td>2.6</td>
<td>7</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>/</td>
<td>3.5</td>
<td>3.5</td>
<td>10</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>/</td>
<td>3</td>
<td>3</td>
<td>24</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>7.3</td>
<td>10.4</td>
<td>30</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>3.4</td>
<td>4.2</td>
<td>14</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>1.5</td>
<td>12.2</td>
<td>24</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>1.3</td>
<td>1.5</td>
<td>8</td>
<td>Patchy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient No.</td>
<td>Duration of enhancement on CT (h)</td>
<td>Oliguria</td>
<td>UOsm/UNa</td>
<td>FENa (%)</td>
<td>Dark urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>72</td>
<td>−</td>
<td>300/42</td>
<td>2.2</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>/</td>
<td>−</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>/</td>
<td>−</td>
<td>381/99</td>
<td>2.1</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>72</td>
<td>−</td>
<td>306/44</td>
<td>0.6</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>21</td>
<td>−</td>
<td>276/46</td>
<td>0.8</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>24</td>
<td>−</td>
<td>289/49</td>
<td>0.5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>41 ±</td>
<td></td>
<td>308/26</td>
<td>1</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>/</td>
<td>±</td>
<td>/71</td>
<td>1.5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>48</td>
<td>−</td>
<td>369/49</td>
<td>0.6</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>/</td>
<td>−</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>/</td>
<td>−</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>36</td>
<td>−</td>
<td>274/31</td>
<td>0.5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>/</td>
<td>−</td>
<td>408/84</td>
<td>2.2</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>/</td>
<td>−</td>
<td>448/7</td>
<td>0.1</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>48</td>
<td>−</td>
<td>388/58</td>
<td>0.5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>96</td>
<td>−</td>
<td>257/35</td>
<td>0.3</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>24</td>
<td>−</td>
<td>228/63</td>
<td>0.2</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>48</td>
<td>−</td>
<td>292/14</td>
<td>0.4</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>24</td>
<td>−</td>
<td>170/33</td>
<td>12</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>24</td>
<td>−</td>
<td>267/18</td>
<td>0.5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>72</td>
<td>+</td>
<td>206/54</td>
<td>5</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>/</td>
<td>−</td>
<td>159/30</td>
<td>0.7</td>
<td>−</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Taken before exercise
UOsm (mOsm/l), UNa (mEq/l)
CT, computed tomography; ARF, acute renal failure
### Our Series (22 Patients)

<table>
<thead>
<tr>
<th>Serum myoglobin (ng/ml)</th>
<th>CPK (U/l)</th>
<th>Myoglobinuria</th>
<th>Kidney biopsy</th>
<th>Hypouricemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>88</td>
<td>292</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>/</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>274</td>
<td>1650</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>90</td>
<td>42</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>100</td>
<td>998</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>35</td>
<td>1323</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>85</td>
<td>250</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>/</td>
<td>73</td>
<td>/</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>120</td>
<td>930</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>/</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>/</td>
<td>/</td>
<td>/</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>70</td>
<td>52</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>40</td>
<td>116</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>/</td>
<td>/</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>49</td>
<td>312</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>67</td>
<td>329</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>75</td>
<td>696</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>67</td>
<td>242</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>420</td>
<td>355</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>47</td>
<td>530</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>/</td>
<td>428</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>/</td>
<td>459</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>
(Fig. 25). He had run three 200-m races in an athletics meeting. Several hours later, vomiting and loin pain occurred. The pain became severe, and he attended an emergency outpatient unit during the night. The findings did not suggest myoglobinuria. A plain CT scan 24 h after the administration of a contrast medium revealed multiple wedge-shaped contrast-enhanced areas. At one area in the left kidney (Fig. 25, arrows), kidney function was almost normal, and the excretion of contrast medium to the renal medulla was observed by dynamic CT.

Patient 5: a 27-year-old man (a physician in our department)

This patient was the first case of ALPE in which a bone scan with $^{99m}$Tc-methylene diphosphonate (MDP) showed patchy findings (see Fig. 18) (the details are given in Chap. 3, Sect. 4). Severe abdominal pain developed after skiing. He consulted our hospital under a self-diagnosis of acute pancreatitis.

Patient 6: a 16-year-old male high-school student

This patient was the first case in which magnetic resonance imaging (MRI) revealed a patchy lesion (Fig. 26). Lumbar pain occurred after a weightlifting session, and he took 75 mg/day diclofenac sodium for 1 week. However, he did not stop weightlifting. On December 7, 1985, fever, nausea, and vomiting occurred. On December 9, he attended our hospital with severe loin pain. His serum creatinine level had increased from 0.8 mg/dl (before onset) to 1.2 mg/dl. CT 5 h after IVP showed several wedge-shaped contrast-enhanced areas in the right kidney (Fig. 27). After 4 days, MRI...
revealed low-signal-intensity areas that were consistent with the wedge-shaped contrast-enhanced areas on CT [35].

Patient 7: a 17-year-old male student
This patient was the first case in which ALPE developed in the presence of renal hypouricemia [3]. On September 26, 1984, he participated in a 400-m race in a school athletics meeting. On September 27, nausea and vomiting occurred about 12 h later at 0100 hours, and then bilateral loin pain and abdominal pain developed. Because
colicky pain persisted, he attended the Emergency Outpatient Unit of our hospital at 2200 hours on September 28. Bilateral knock pain at the costovertebral angle was marked. His urine color was normal, and his urinary protein level was 2+. Urinary sediment showed 40 erythrocytes per visual field. His serum creatinine and uric acid levels and fractional excretion of uric acid (FEUA) were 7.3 mg/dl, 5.5 mg/dl, and 28.7%, respectively. Delayed CT was performed 12, 18, 41, and 96 h after intravenous injection of 40 ml contrast medium (67% sodium iothalamate) on October 1. Diffuse to patchy contrast enhancement was observed in the kidneys (Fig. 28), which persisted for 41 h. The patient’s serum creatinine level reached a peak of 8.1 mg/dl before the administration of contrast medium, but decreased to 6.7 mg/dl on October 2 after conservative therapy. His peak serum uric acid level was 5.6 mg/dl, but this decreased to 5.1 mg/dl on October 2. However, kidney hypofunction persisted for 18 days. On October 15, his serum creatinine and uric acid levels and FEUA were 0.9 mg/dl, 0.6 mg/dl, and 79.3%, respectively. A kidney biopsy on October 9 suggested that the acute tubular necrosis had healed. There was no uric acid deposition in the kidney tissue.

Patient 8: a 22-year-old man
This patient developed ALPE in the presence of renal hypouricemia [3]. He caught a cold, and took aspirin at 400 mg, ethenzamide at 150 mg, and acetaminophen at 300 mg on October 8 and 9, 1987. On October 10, he participated in two 100-m races
Our Series (22 Patients)

29 Patients at a district athletics meeting. After 4h, nausea and vomiting occurred. On October 11, malaise, loin pain, epigastric pain, and slight fever developed, and the patient attended a hospital on October 12. Urinalysis showed trace protein. However, his urinary sediment was normal, and his serum creatinine and uric acid levels were 3.9 mg/dl and 2.7 mg/dl, respectively. Thereafter, his serum creatinine level gradually decreased to 3.1 mg/dl, 1.4 mg/dl, and 1.0 mg/dl on October 15, 19, and 27, respectively. However, his serum uric acid level also decreased to 1.7 mg/dl, 1.0 mg/dl, and 0.4 mg/dl, respectively, suggesting renal hypouricemia. On October 30, the patient was admitted to our hospital for further examination. On October 17, 19, and 31, his FEUA values were 60%, 53%, and 58%, respectively (Fig. 29). On October 22, plain CT revealed swelling of the bilateral kidneys. However, the CT attenuation value in the medulla was not high, and there was no massive deposition of uric acid. Contrast-enhanced CT 10 min after the administration of contrast medium showed no wedge-shaped contrast enhancement (Fig. 30). Thereafter, wedge-shaped contrast media enhancement was not attested. A kidney biopsy performed on November 4 revealed the healing stage of acute tubular necrosis. As the patient had renal hypouricemia, a test with benzbromarone and pyrazinamide was performed on November 12 to clarify the mechanism involved in the disordered kidney transport of uric acid. A presecretory reabsorption defect was suggested.

Patient 9: a 24-year-old man

This patient participated in a 200-m relay race at an athletics meeting on October 10. After dinner, a dull pain in his left flank occurred and gradually worsened, but it differed from colic. There was no decrease in urine volume or dark urine. At 2330 hours, the patient attended the Emergency Outpatient Unit of our hospital because of the pain. An intramuscular injection of scopolamine butylbromide relieved the

![Figure 29. The clinical course of ALPE complicated by renal hypouricemia](image-url)
pain slightly. However, ureteral stone was suspected, and the patient was referred to our department. His serum creatinine and myoglobin levels were 2.1 mg/dl and 120 ng/ml (reference value, <60), respectively. Delayed CT after the administration of contrast medium on October 12 showed wedge-shaped contrast enhancement in the bilateral kidneys. On October 16 the pain disappeared, and on October 17 his serum creatinine level was 1.1 mg/dl.

Patient 10: a 31-year-old man

This patient developed loin pain after two 100-m races at an athletics meeting. In late May 1983, he caught a cold, but did not take any medication. On June 5, he participated in various events, including two 100-m races, at an athletics meeting. That evening, bilateral lumbar pain occurred, and he could not sleep. On June 6, the patient attended the Department of Orthopedics in our hospital. Under a diagnosis of lumbar pain, indomethacin suppositories were administered for 3 days. He attended the Department of Internal Medicine in our hospital on June 8. At the first visit, his blood pressure was 130/80 mmHg, and his body weight was 64.5 kg (3 kg weight gain). The patient was negative for C-reactive protein (CRP), plus/minus for urinary protein, and positive for occult blood. His serum creatinine and uric acid levels were 4.2 mg/dl and 14.7 mg/dl, respectively, but decreased to 1.4 mg/dl and 7.0 mg/dl, respectively, on June 17. On June 24, his serum creatinine level was 1.2 mg/dl. On June 30, his body weight returned to 61.5 kg.

Patient 11: a 33-year-old man

This patient was the first case in our series in which ALPE was detected with acute renal failure due to unknown etiology. On September 19, 1976, he ran two 100-m races at an athletics meeting. On September 20, vomiting, diarrhea, and upper abdominal pain developed, and the patient attended our department. His serum creatinine and uric acid levels were 5.0 mg/dl and 17.0 mg/dl, respectively. The pain persisted for 1
day. However, these levels decreased to 3.2 mg/dl and 9.6 mg/dl, respectively, on September 24, and to 1.3 mg/dl and 6.7 mg/dl, respectively, on October 1. IVP on October 8 revealed no abnormalities, which suggested acute interstitial nephritis. However, no kidney biopsy was performed.

Patient 12: a 34-year-old man

This patient was admitted to hospital because of minimal change nephrotic syndrome. While in hospital he went out for exercise. In October 1987, minimal change nephrotic syndrome recurred, and steroid pulse therapy achieved complete remission. He was then admitted for maintenance therapy with prednisolone at 25 mg and mizoribine at 100 mg. During this time, he left our hospital and made a flight in a light plane (cycling-type exercise) for about 1 h on December 14. After 16 h, loin pain occurred, and his serum creatinine level was 3 mg/dl. On December 17, delayed CT 12 h after the administration of contrast medium revealed many wedge-shaped contrast-enhanced areas in the bilateral kidneys (Fig. 32). A bone scan with MDP showed an uneven abnormal accumulation of an isotope in the parenchyma of the bilateral kidneys (Fig. 33). On December 21, his serum creatinine level returned to 1.1 mg/dl, and on December 25, neither kidney CT nor delayed CT showed any abnormal findings.
Fig. 32. Delayed CT 12 h after the administration of contrast medium (the *upper* and *lower* rows show different slice levels)

Fig. 33. Bone scan with MDP. An uneven abnormal accumulation of an isotope was seen in the parenchyma of the bilateral kidneys
Patient 13: a 21-year-old man

This patient, who had autosomal dominant polycystic kidney disease (ADPKD), almost drowned and then developed ALPE. On July 20, 1990, he nearly drowned in the sea at 1500 hours, and was brought to our hospital by ambulance for dyspnea and severe loin pain at 1620 hours. On admission, metabolic acidosis was observed. His CRP, serum creatinine, CPK, amylase, and urinary protein levels were 1+, 1.5 mg/dl, 116 U/l, 592 U/l (derived from the salivary gland), and 2+, respectively. His body temperature was 37.7°C, and his blood pressure was 110/60 mmHg. His pulse and respiratory rate were 120/min and 22/min, respectively. Delayed CT 6h after the administration of contrast medium showed wedge-shaped contrast enhancement in the noncystic renal parenchyma (Fig. 34). On July 24, a bone scan with MDP revealed patchy lesions (Fig. 35). His serum creatinine level was 1.3 mg/dl, which had decreased to 1.0 mg/dl on July 27. The patient was then discharged.

Patient 14: a 15-year-old boy

This patient was diagnosed as having acute enteritis. On May 31, 1993, upper abdominal pain occurred at the end of baseball training in the evening. After going home, severe pain, watery diarrhea, vomiting, and fever (until June 1) were noted. On June 1, he was diagnosed at a local clinic as having acute enteritis and underwent drip

![Fig. 34. Delayed CT 6h after the administration of contrast medium to an autosomal dominant polycystic kidney disease (ADPKD) patient with ALPE. Top. Wedge-shaped contrast enhancement can be seen in the noncystic renal parenchyma region at onset. Bottom. CT under the same conditions in the recovery phase did not show wedge-shaped contrast enhancement]
Fig. 35. Bone scan image with MDP in the same patient as in Fig. 34. A patchy lesion was observed. However, it was unclear whether this finding suggested ALPE or ADPKD.

Fig. 36. Top. Plain CT showing a renal swelling (serum creatinine 3.7 mg/dl). Bottom. Delayed CT 18 h after the administration of contrast medium showed a diffuse uptake, although the patient’s serum creatinine level had decreased to 1.8 mg/dl.

Infusion. However, on June 3, his serum creatinine level was 3.7 mg/dl. He was admitted to the local clinic, and treated with an antibiotic. On June 7, his serum creatinine level further increased to 5.1 mg/dl, and he was referred to our department. On admission, there were no changes in urine volume. His blood pressure was 140/60 mmHg, and his body temperature was 36.7°C. His serum creatinine, uric acid, UOsm, UNa, and FENa values were 4.3 mg/dl, 11.0 mg/dl, 448 mOsm/l, 7.0 mEq/l, and 0.1 %, respectively. On June 10 (recovery phase), delayed CT 18 h after the administration of contrast medium (serum creatinine level 1.8 mg/dl) showed diffuse contrast enhancement (Fig. 36). In our series, only this patient showed diffuse contrast enhancement with a
Our Series (22 Patients) 35

serum creatinine level of 1.8 mg/dl. The reason why there was no patchy contrast enhancement was unclear. On June 22, his serum creatinine level decreased to 0.9 mg/dl.

Patient 15: a 26-year-old man

This patient, who had ADPKD, developed ALPE after a sprint. On October 1, 1995, he participated in two 100-m races at an athletics meeting in the morning. After a few hours, severe loin pain occurred, and he attended our department the following morning. There were no other abnormal findings, and his blood pressure, pulse, and serum creatinine values were 120/66 mmHg, 64/min, and 1.6 mg/dl (serum creatinine level before onset 0.9 mg/dl), respectively. On October 2, delayed CT 4 and 24 h after the administration of contrast medium showed patchy lesions (Fig. 37). On October 14, his serum creatinine level returned to 1.1 mg/dl, and CT 4 h after the administration of contrast medium showed no contrast enhancement.

Patient 16: a 19-year-old man

On June 13, 1998, this patient participated in 100-m, 400-m, and 1500-m time-trial races at 1400 hours. Left loin pain occurred at 1600 hours. He considered that he had caught a cold, and took a commercially available drug for colds and an analgesic agent. Initially, pain was marked in the sitting position, and became less marked in the supine position. However, it gradually became worse even in the supine position, and he attended the Emergency Outpatient Unit of our hospital at 0500 hours on June 14. His serum creatinine, total bilirubin, and CPK levels were increased to 2.1 mg/dl, 2.8 mg/dl (the reason for an increase in total bilirubin was unclear), and 329 U/L, respectively, and the patient was referred to our department. On June 14, CT 24, 48, and 96 h after the administration of contrast medium showed patchy lesions (Fig. 38)

![Fig. 37. ALPE in a patient with ADPKD. Delayed CT 4, 24, and 48 h after the administration of contrast medium. Wedge-shaped contrast enhancement can be seen in the noncystic renal parenchyma. This finding was more marked after 4 h than after 24 h](image-url)
Exercise-Induced Acute Renal Failure

Fig. 38. Delayed CT 24, 48, and 96 h after the administration of contrast medium

(serum creatinine level 2.6 mg/dl). On June 17, T2-weighted images (T2WI) on MRI revealed patchy changes in signal intensity without contrast medium (see Fig. 22). Patchy lesions could be visualized by dynamic MRI (Fig. 39) and by a bone scan with MDP (Fig. 40).

Patient 17: a 19-year-old man
This patient was treated under a diagnosis of acute enteritis. He participated in festival training, such as running and jumping with sticks, for 4 h per day from August 16 until August 20, 1998. On August 18, abdominal pain occurred, followed by nausea on August 19. He attended a local clinic, and was treated under a diagnosis of acute enteritis. However, on August 20, the abdominal pain became worse, and he attended the Emergency Outpatient Unit of our hospital at 2200 hours. His serum creatinine level had increased to 3.5 mg/dl. On August 22, delayed CT showed patchy lesions (Fig. 41). On August 25, his serum creatinine level returned to 1.2 mg/dl.

Patient 18: a 41-year-old man
This patient (Case 1 in Fig. 57) and his son developed ALPE in the presence of renal hypouricemia [36]. After two 150-m sprints and rope skipping (40 skips) in a town athletics meeting, he developed ALPE. Gene analysis was performed to check for renal hypouricemia. The patient’s son also developed ALPE (Case 2 in Fig. 57). The details are given in Chap. 10, Sect. 1.
Our Series (22 Patients)

Fig. 39. MRI before and after the administration of Gd–DTPA. Upper row, before the administration of Gd–DTPA (TR 11.0, TE 4.2/1). Middle row, 2 min after the bolus administration of Gd–DTPA at 15 ml (TR 110, TE 4.1/1). Lower row, 4 min after the bolus administration (TR 110, TE 4.1/1). At the arrows in the lower row, the uptake of Gd–DTPA was low in some areas.

Fig. 40. Bone scan with MDP. The patchy findings were more marked in the left kidney.

Patient 19: a 39-year-old man

This patient required hemodialysis for ALPE. Delayed CT and a bone scan with MDP in the recovery phase showed patchy lesions (these imaging procedures were performed in conjunction with another patient with myoglobinuric acute renal failure due to a malignant syndrome). On July 19, 1999, the patient fell into the water while fishing in a mountain stream, and was carried about 100 m in a few minutes while struggling all the time. As a precaution, he was admitted to a local clinic overnight. There were no abnormal laboratory data. However, at 0300 hours on July 21, he attended the Emergency Outpatient Unit of our hospital with severe bilateral loin...
pain. His serum creatinine level was 7.3 mg/dl. Under a diagnosis of ALPE, he was admitted to our hospital and hemodialysis was performed. On August 16, his serum creatinine level returned to 1.2 mg/dl. CT on July 31 revealed patchy lesions (Fig. 42).

Patient 20: a 27-year-old man

In this case, ALPE was complicated by nocturnal hemoglobinuria. At the age of 20 years, the patient developed nocturnal hemoglobinuria. He had been treated in the Department of Hematology and Immunology in our hospital. On June 18, 2000, he participated in a practice baseball game from 0900 hours until 1500. At 1700 hours, right abdominal and loin pain occurred. On June 19, his serum creatinine level was 3.4 mg/dl (before onset, 0.7 mg/dl). On June 22, CT 24 h after the administration of contrast medium showed patchy lesions (Fig. 43). On June 26, his serum creatinine level had returned to 1.2 mg/dl.

Patient 21: a 14-year-old boy

This patient and his father (Patient 18) developed ALPE in the presence of renal hypouricemia [36] (Case 2 in Fig. 57). The son developed ALPE after participating in two 400-m races, a mock cavalry battle, and a tug of war in an athletics meeting. At a local clinic, a nonsteroidal anti-inflammatory drug (NSAID) was administered orally under a diagnosis of “muscular pain,” and the condition was exacerbated. Gene
**Fig. 42.** Delayed CT 24 h after the administration of contrast medium. Patchy contrast enhancement can be seen in the right kidney.

**Fig. 43.** Delayed CT 24 and 48 h after the administration of contrast medium. Contrast enhancement can be detected 48 h after administration, although it is less marked.
analysis was performed, and MRI revealed patchy lesions. The details are given in Chap. 10, Sect. 1.

Patient 22: a 16-year-old male high-school student

In this patient, acute pyelonephritis was suspected in the presence of mycoplasma pneumonia. At the age of 12 years, he developed fever and loin pain, and was treated under a diagnosis of acute right pyelonephritis. After entering high school, he joined the badminton team. He trained for 4 h or more per day from January 4, 2005. On January 8, he felt very hot during training, and took an antipyretic analgesic for fever (40°C) after exercise. He then stayed at home. However, on January 10, loin pain occurred. The pain did not subside, and he attended a local clinic. Under a tentative diagnosis of acute pyelonephritis, the patient was referred to our department on January 11. On admission, his CRP level was increased to 6.1 mg/dl. He was positive for urinary protein and occult blood. There were no leukocytes in the urinary sediment. Furthermore, his serum creatinine level was 1.3 mg/dl, suggesting kidney dysfunction. His CPK level was slightly increased at 459 U/l. The administration of a cepham antibiotic did not relieve the fever. CT 4 h after the administration of contrast medium showed multiple wedge-shaped contrast-enhanced areas in the bilateral kidneys (Fig. 44). In addition, an infiltrating shadow in the left inferior lung field suggested mycoplasma pneumonia, and the agent was switched to a macrolide antibiotic, after which the pneumonia rapidly subsided. His serum creatinine level reached a maximum (1.5 mg/dl) 4 days after admission, but then decreased to 0.9 mg/dl at discharge. After the patient’s condition had improved, CT showed no wedge-shaped contrast enhancement in the kidneys. The mycoplasma pneumonia may have caused the fever, which was complicated by ALPE.

Fig. 44. Delayed CT 4 h after the administration of contrast medium. Top. In the initial phase, wedge-shaped contrast enhancement was observed in the bilateral kidneys. Bottom. In the recovery phase, there was no wedge-shaped contrast enhancement
2 Delayed CT, MRI, and Bone Scan with MDP

In our series, we reviewed examples of wedge-shaped contrast enhancement. Many patients showed swelling of the kidney. Delayed CT showed wedge-shaped contrast enhancement from 3 to 24h after the administration of a contrast medium, during which time the patient’s serum creatinine level ranged from 1.2 to 3.5 mg/dl. After the patient’s condition had improved, no swelling of the kidney or wedge-shaped contrast enhancement was observed in any patient under the same conditions, suggesting that the lesions were reversible.

MRI and a bone scan with MDP showed wedge-shaped contrast enhancement in some patients, although these procedures were less sensitive than CT. Patchy lesions could be visualized by a bone scan with MDP in Patients 5 (Fig. 18), 12 (Fig. 33), 13 (Fig. 35), and 16 (Fig. 40). This visualization was achieved by MRI in Patients 6 [35] (Fig. 26), 16 (Fig. 22 and Fig. 39), and 21 (Fig. 45). In the future, ultrasonography with Levovist will facilitate the visualization of lesions.

3 Kidney Biopsy

In 5 of the 22 patients, a kidney biopsy was performed. The findings suggested that these patients were in the recovery phase of acute tubular necrosis.
Chapter 6
Summary of 155 Cases Collected from the Literature

For this collection of data, we selected patients with acute kidney dysfunction or acute renal failure who met the above criteria for exercise-induced acute renal failure (ALPE), and who also matched our description. We collected a total of 155 patients with ALPE. The first 118 patients [2,3,22,27,30,34,35,37–95, Yamagata (personal communication, 1986), Ishikawa (unpublished results, 1994), Kadowaki (personal communication, 1996)] included 20 who we encountered before December 2000, and the remaining 37 patients [36,96–126] included 2 who we encountered between January 2001 and December 2004.

A summary of these 155 patients is shown in Table 4. We collected a total of 173 patients by adding 18 more patients [127–136] including 1 who we encountered before December 2005.

1 Background

The ages of the 150 patients whose ages were known ranged from 10 to 54 years, with a mean of 21.7 ± 7.8 years (Fig. 46). ALPE was particularly frequent in patients aged 14–25 years. Among 154 of the patients, 143 (92.9%) were male. It seems that males sprint more frequently than females.

Furthermore, 28 (46%) of the 61 patients in whom the presence or absence of a cold was recorded had caught a cold prior to exercise, and 23 (34%) of 68 patients took cold medicine or antipyretic analgesics (Fig. 47).

2 Findings and Laboratory Data on the First Visit

The findings for the patients on their first visit to a clinician included loin pain, nausea/vomiting (96%), and slight fever (76%) (Fig. 48). Among our patients, 18 (85.7%) of 21 patients were positive for C-reactive protein (CRP), 8 (38.1%) of 21 patients had hypertension, and weight gain was noted in 13 (65.0%) of 20 patients, suggesting overhydration.

The mean serum creatinine level on the first visit was 4.7 ± 2.8 mg/dl. The mean maximum serum creatinine level was 6.0 ± 3.1 mg/dl (Fig. 49, Table 4). The prognosis
Exercise-Induced Acute Renal Failure

Table 4. Summary of the cases of 155 patients with exercise-induced acute renal failure (ALPE)

<table>
<thead>
<tr>
<th>Number of cases described</th>
<th>Mean (range) or number of positive cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>21.7 ± 7.8 (10–54)</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 143 (92.9%), Female 11</td>
</tr>
<tr>
<td>Prodrome (flu-like symptoms)</td>
<td>28 (45.9%)</td>
</tr>
<tr>
<td>Analgesic ingestion</td>
<td>23 (33.8%)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>111 (95.7%)</td>
</tr>
<tr>
<td>Slight fever</td>
<td>47 (75.8%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>35 (51.5%)</td>
</tr>
<tr>
<td>Duration of loin pain (days)</td>
<td>5.2 ± 3.4 (1–14)</td>
</tr>
<tr>
<td>Initial serum creatinine (before urography) (mg/dl)</td>
<td>4.7 ± 2.8 (0.6–15)</td>
</tr>
<tr>
<td>Maximum serum creatinine (mg/dl)</td>
<td>6.0 ± 3.1 (1.2–15)</td>
</tr>
<tr>
<td>Duration of renal dysfunction (days)</td>
<td>13.6 ± 9.0 (3–60)</td>
</tr>
<tr>
<td>Wedge-shaped contrast enhancement by CT</td>
<td>+53 (93.0%)</td>
</tr>
<tr>
<td>Duration of wedge-shaped lesions (h)</td>
<td>48.3 ± 25.8 (10–120)</td>
</tr>
<tr>
<td>Patchy lesions by MDP bone scan</td>
<td>+18 (64.3%)</td>
</tr>
<tr>
<td>Oliguria</td>
<td>24 (19.0%)</td>
</tr>
<tr>
<td>UNa (mEq/l)</td>
<td>46.7 ± 21.7 (14–99)</td>
</tr>
<tr>
<td>FENa (%)</td>
<td>2.0 ± 2.2 (0.07–12)</td>
</tr>
<tr>
<td>Myoglobinuria</td>
<td>0</td>
</tr>
<tr>
<td>Serum myoglobin (ng/ml)</td>
<td>115.6 ± 123.6 (3.5–728)</td>
</tr>
<tr>
<td>(Ratio to normal)</td>
<td>(1.6 ± 1.3 (1–7))</td>
</tr>
<tr>
<td>CPK (U/l)</td>
<td>354.4 ± 486.8 (18–2863)</td>
</tr>
<tr>
<td>(Ratio to normal)</td>
<td>(2.0 ± 1.7 (1–8.8))</td>
</tr>
<tr>
<td>Renal hypouricemia</td>
<td>76 (57.1%)</td>
</tr>
<tr>
<td>Recurrence of ALPE</td>
<td>31 (20.0%)</td>
</tr>
</tbody>
</table>

MDP, \(^{99m}\text{Tc-methylene diphosphonate}\)

![Fig. 46. Age distribution in 150 patients with ALPE. ALPE frequently develops at 14–25 years of age](image-url)
Summary of 155 Cases Collected from the Literature

**Fig. 47.** Proportions of patients with a cold and those taking antipyretic analgesics before the onset of ALPE

<table>
<thead>
<tr>
<th>Prodrome (flu-like symptoms)</th>
<th>+</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>45.9 (28/61)</td>
<td></td>
<td>54.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antipyretic analgesics</th>
<th>+</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>33.8 (23/68)</td>
<td></td>
<td>66.2</td>
</tr>
</tbody>
</table>

**Fig. 48.** Summary of 155 patients with ALPE

**Fig. 49.** Distribution of maximum serum creatinine levels in patients with ALPE. *, patients who required hemodialysis

for all patients was good. However, 31 (20.0%) of 155 patients required dialysis therapy, or 29 (21.0%) of 138 patients for whom serum creatinine levels were recorded, required dialysis therapy.

Serum levels of creatine phosphokase (CPK) (Fig. 50) were 100 mU/ml or less in 31 patients, and 300 mU/ml or more in 36 patients. The mean was 2.0 ± 1.7 times higher than the reference value. No values were more than 9 times higher than the reference value. However, minimal rhabdomyolysis was suggested.

The serum myoglobin level (Fig. 51) was 100 ng/ml or less in most patients \(n = 42\), and exceeded 300 ng/ml in only 4 patients. The mean was 1.6 ± 1.3 times higher than the reference value. No values were more than 7 times higher than the reference value.
value. No patient showed myoglobinuria. In other words, the serum CPK and myoglobin levels in ALPE patients were normal or slightly increased. However, in none of these patients were these parameters more than $10-20$ times higher than the reference values, which is different from the values found in myoglobinuric acute renal failure [11,137].

The urinalysis showed that there were no abnormalities in some patients, but mild proteinuria and hematuria were observed in others. $\text{UOsm} = 284 \pm 69 \text{mOsm/l} \ (n = 23)$, and $\text{UNa} = 47 \pm 22 \text{mEq/l} \ (n = 28)$. The mean values of $\text{FENa}$ were $2.0 \pm 2.2\%$ and less than $1\%$ in about $50\%$ of patients, and $1\%$ or more in the remaining patients.

3 Renal Hypouricemia

Renal hypouricemia was observed in $76 \ (57\%)$ of the $133$ patients in whom the serum levels of uric acid were recorded. Patients with a serum uric acid level of $2.0 \text{mg/dl}$ or less at baseline were regarded as having hypouricemia.

4 Imaging Findings (Wedge-Shaped Patchy Renal Ischemia)

Wedge-shaped contrast enhancement was detected in $53 \ (93\%)$ of the $57$ patients who underwent delayed computed tomography (CT) (Fig. 52). However, in the other $4$ patients, CT was performed when the serum creatinine level was high.
5 Kidney Biopsy

In 54 patients, a kidney biopsy was performed 13.2 ± 8.9 days after onset (n = 32). In all patients, the findings suggested either acute tubular necrosis or its recovery phase. The underlying diseases included kidney diseases such as IgA nephropathy [138], minimal change nephrotic syndrome [139], autosomal dominant polycystic kidney disease (ADPKD) [140], and cystinuria [67].

6 Relapse

Relapse was detected in 31 (20%) of the 155 patients (Fig. 53). In one patient, 5 recurrent episodes were noted [117].
Chapter 7
Exercise

1 Type of Exercise

As shown in Fig. 54, the types of exercise taken by the patients consisted of a track race (a short-distance sprint such as a 200-m race), soccer, a swimming race, baseball, weightlifting, and a bicycle race, in all of which an intense power output per second or per minute is repeated. However, a single 100-m race was less likely to cause exercise-induced acute renal failure (ALPE). Several 200-m or 100-m races frequently caused ALPE. Repeated anaerobic exercise may be a risk factor.

The time of onset was often September or October, when many athletics meetings and sports festivals are held (Fig. 55).

2 Anaerobic Exercise

Anaerobic exercise (Table 5) is intense exercise requiring great muscle strength, such as sprinting and weightlifting. The activity is performed over a short period of time via explosive energy production/consumption [141–143]. A characteristic of such exercise is that can be performed via anaerobic glycolysis under a condition of oxygen deficiency. However, the duration of such exercise is limited to 1 min or less; it is impossible to continue anaerobic exercise for many hours. In anaerobic exercise it is type II muscle fibers (white muscle) that are mainly utilized.

<table>
<thead>
<tr>
<th>Table 5. Aerobic and anaerobic exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise, duration of exercise</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Type of exercise</td>
</tr>
<tr>
<td>Mainly utilized muscle fibers</td>
</tr>
<tr>
<td>Energy source</td>
</tr>
</tbody>
</table>
Exercise-Induced Acute Renal Failure

Fig. 54. Type of exercise causing ALPE. In most patients, anaerobic exercise was involved.

Fig. 55. Timing of ALPE development. The number of patients was highest in September, when many athletics meetings and sports festivals are held.
### Table 6. Types of muscle fibers

<table>
<thead>
<tr>
<th>Type of muscle fiber</th>
<th>Type I</th>
<th>Type II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Red muscle</td>
<td>White muscle</td>
</tr>
<tr>
<td></td>
<td>Aerobic exercise</td>
<td>Anaerobic exercise</td>
</tr>
<tr>
<td>Glycogen</td>
<td>Small amount</td>
<td>Large amount</td>
</tr>
<tr>
<td>Enzyme activity of glycolysis</td>
<td>Small amount</td>
<td>Large amount</td>
</tr>
<tr>
<td>Enzyme activity of oxidation</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Mitochondria</td>
<td>Large amount</td>
<td>Small amount</td>
</tr>
<tr>
<td>Myoglobin</td>
<td>Large amount</td>
<td>Small amount</td>
</tr>
</tbody>
</table>

### 3 Involvement of Type II Muscle Fibers

Type II muscle fibers (white muscle, fast muscle) (Table 6) contribute to rapid muscle contraction by using energy obtained from stored ATP, and ATP production from creatine phosphate and anaerobic glycolysis of glycogen. However, the myoglobin content of these fibers is low [144,145], which may lead to less marked increases in serum myoglobin and creatine phosphokinase (CPK) in patients with ALPE.
Chapter 8
Loin Pain

1 Timing of Onset and Duration

In these patients, pain mainly developed 3–12 h (1–48 h) after exercise, and persisted for 1–14 days, with a mean of 5 days.

2 Sites and Features of Pain

Table 7 shows the sites and features of reported pain. Most patients complained of loin pain. However, some patients complained of abdominal pain. The grade of pain in our patients was severe in 10 of the 22 patients, making lying down, sleeping, and driving impossible.

Because of the severe pain, the physician (Patient 5) with exercise-induced acute renal failure (ALPE) made a self-diagnosis of acute pancreatitis. Initially, most patients are diagnosed as having ureteral stone, but some physicians diagnose “lumbar pain” or lumbar disc hernia.

<table>
<thead>
<tr>
<th>Site of pain</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loin pain</td>
<td>103</td>
</tr>
<tr>
<td>Lumbar pain</td>
<td>23</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>28</td>
</tr>
<tr>
<td>Anterior chest pain</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>155</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feature of pain</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rolling over due to acute severe pain</td>
<td>3</td>
</tr>
<tr>
<td>Cannot sleep at night</td>
<td>3</td>
</tr>
<tr>
<td>Cannot drive a car due to acute severe pain</td>
<td>2</td>
</tr>
<tr>
<td>Colicky</td>
<td>2</td>
</tr>
</tbody>
</table>
3 Mechanism Involved in Pain

The mechanism involved in the pain remains to be clarified. However, we speculate that it is vascular spasm-related pain, i.e., the involvement of renal angina, based on the following findings. In our experience, catheter end-related obstruction of the renal artery causes severe loin pain during selective renal angiography in patients undergoing dialysis, and one study reported that cerebrovascular spasm in the presence of subarachnoid hemorrhage persisted for 1 week in some patients. Acute tubular necrosis rarely induces renal swelling-related pain (nephralgia as a type of visceral pain), which may differ from the pain described above. The loin pain hematuria syndrome reported in the UK was related to renal infarction [146–148]. Loin pain in the presence of hemorrhagic fever with renal syndrome was associated with retroperitoneal edema [18]. These mechanisms differed from the mechanism involved in pain related to ALPE.
Chapter 9
Renal Hypouricemia

Risk factors for exercise-induced acute renal failure (ALPE) include anaerobic exercise, renal hypouricemia, administration of antipyretic analgesics for cold, and dehydration. We review renal hypouricemia here and in Chap. 10.

1 Serum Creatinine and Uric Acid Levels

In 1990, we reported that 3 (23%) of 13 patients with ALPE had renal hypouricemia [3]. Previously, Erley et al. [28] had reported that patients with renal hypouricemia frequently developed acute renal failure. However, we were the first to report that these patients developed exercise-induced acute renal failure (ALPE) [3]. In our 3 patients with renal hypouricemia, the mean serum creatinine and uric acid levels in acute renal failure were 5.1 ± 2.6 mg/dl and 4.7 ± 1.7 mg/dl, respectively (Fig. 56). In the remaining 10 patients without renal hypouricemia, the mean serum creatinine and uric acid levels were 3.1 ± 1.6 mg/dl and 11.4 ± 4.2 mg/dl, respectively. In the recovery phase, these levels in the hypouricemia patients were 1.1 ± 0.3 mg/dl and 0.8 ± 0.2 mg/dl, respectively. The mean FEUA was 58.4 ± 18.7%. In the 10 patients without hypouricemia, the mean serum creatinine, uric acid, and FEUA values were 1.1 ± 0.1 mg/dl, 6.1 ± 1.2 mg/dl, and 7.8 ± 3.0%, respectively.

Previously, the disordered renal transport of uric acid in patients with renal hypouricemia had been explained by a 4-component model. In our review, 59% of the patients with ALPE and renal hypouricemia were classified as the presecretory reabsorption defect type, followed by the total defect in uric acid transport (no secretion and no reabsorption) and total reabsorption defect types (Table 8).

2 Comparison of Patients With and Without Renal Hypouricemia

Of the 155 cases of patients with ALPE collected from the literature, we examined the presence or absence of renal hypouricemia in 133 for whom the serum levels of uric acid were reported (Table 9). The mean ages in the renal hypouricemia and non-renal hypouricemia groups were 20.2 ± 7.4 years and 23.3 ± 8.4 years, respectively. In the
Table 8. Types of disordered renal uric acid transport in 76 patients with renal hypouricemia and ALPE

- Presecretory reabsorption defect: 29 (59.2%)
- Total defect in uric acid transport (no secretion and no reabsorption): 10 (20.4%)
- Total or subtotal reabsorption defect: 8 (16.3%)
- Postsecretory reabsorption defect: 1 (2.0%)
- Increased secretion: 1 (2.0%)
- Unknown or no description: 27

Table 9. Comparison of ALPE patients with and without renal hypouricemia

<table>
<thead>
<tr>
<th>n</th>
<th>Renal hypouricemia</th>
<th>No renal hypouricemia</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>76</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>20.2 ± 7.4 (n = 75)</td>
<td>23.3 ± 8.4 (n = 57)</td>
<td>0.0247</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>11.5:1</td>
<td>10.4:1</td>
<td>NS</td>
</tr>
<tr>
<td>Analgesic ingestion</td>
<td>2/16</td>
<td>14/42</td>
<td>NS</td>
</tr>
<tr>
<td>Prodrome (flu-like symptoms)</td>
<td>7/19</td>
<td>18/37</td>
<td>NS</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>57/58</td>
<td>42/45</td>
<td>NS</td>
</tr>
<tr>
<td>Slight fever</td>
<td>19/21</td>
<td>23/35</td>
<td>0.0383</td>
</tr>
<tr>
<td>Duration of loin pain (days)</td>
<td>5.6 ± 4.3 (n = 17)</td>
<td>4.8 ± 2.8 (n = 24)</td>
<td>NS</td>
</tr>
<tr>
<td>Initial serum creatinine (mg/dl)</td>
<td>5.1 ± 2.8 (1.1–15) (n = 61)</td>
<td>4.0 ± 2.6 (0.6–11.3) (n = 42)</td>
<td>0.0489</td>
</tr>
<tr>
<td>Maximum serum creatinine (mg/dl)</td>
<td>6.3 ± 2.9 (1.6–15) (n = 68)</td>
<td>5.6 ± 3.2 (1.2–14.1) (n = 54)</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of renal dysfunction (days)</td>
<td>15.3 ± 9.0 (3–60) (n = 53)</td>
<td>12.4 ± 9.6 (3–60) (n = 44)</td>
<td>NS</td>
</tr>
<tr>
<td>Wedge-shaped lesions by CT scan</td>
<td>16/17</td>
<td>37/39</td>
<td>NS</td>
</tr>
<tr>
<td>Patchy lesion by MDP bone scan</td>
<td>4/7</td>
<td>12/19</td>
<td>NS</td>
</tr>
<tr>
<td>Oliguria</td>
<td>13/57</td>
<td>9/49</td>
<td>NS</td>
</tr>
<tr>
<td>Myoglobinuria</td>
<td>0/40</td>
<td>0/37</td>
<td>(NS)</td>
</tr>
<tr>
<td>Serum myoglobin (ng/ml)</td>
<td>126.4 ± 157.1 (n = 24)</td>
<td>120.0 ± 106.5 (n = 28)</td>
<td>NS</td>
</tr>
<tr>
<td>(Ratio to normal)</td>
<td>1.7 ± 1.4 (n = 28)</td>
<td>1.7 ± 1.3 (n = 31)</td>
<td>NS</td>
</tr>
<tr>
<td>CPK (U/l)</td>
<td>320.4 ± 471.2 (n = 42)</td>
<td>426.0 ± 522.5 (n = 46)</td>
<td>NS</td>
</tr>
<tr>
<td>(Ratio to normal)</td>
<td>1.8 ± 1.5 (n = 52)</td>
<td>2.3 ± 1.9 (n = 49)</td>
<td>NS</td>
</tr>
<tr>
<td>Recurrence of ALPE</td>
<td>23</td>
<td>6</td>
<td>0.0064</td>
</tr>
<tr>
<td>Hypertension</td>
<td>20/39</td>
<td>12/25</td>
<td>NS</td>
</tr>
</tbody>
</table>
former group, the incidence of slight fever, serum creatinine level on the first visit, and recurrence rate were high. This renal hypouricemia group consisted of 76 patients (57%), and this percentage was markedly higher than that in our series (23%, 3/13). Furthermore, we calculated the incidence of ALPE in renal hypouricemia patients based on the incidence of renal hypouricemia in Japan and the proportion of patients with renal hypouricemia in ALPE patients. The incidence of ALPE in renal hypouricemia patients was approximately 50 times higher than that in non-renal hypouricemia patients.

We performed delayed CT after the administration of contrast medium in 11 patients with both ALPE and renal hypouricemia. In 10 of the 11 patients, patchy renal ischemia was noted [4], suggesting that renal ischemic conditions after anaerobic exercise were similar regardless of the presence or absence of renal hypouricemia.

3 Reasons for a High Incidence of ALPE in Patients with Renal Hypouricemia

A high incidence of ALPE was diagnosed in patients with renal hypouricemia because a uric acid transporter encoded by the SLC22A12 gene (uric acid transporter 1 (URAT1)) was identified in 2002 [149], a less marked increase in the serum uric acid level in the presence of acute renal failure facilitated diagnosis, the incidence of renal hypouricemia was high in Japan (0.15% [150] or 0.2%–0.6% [151]), and athletics meetings and sports festivals involving anaerobic exercise in the events are held as annual functions in schools, companies, and towns. These annual functions originated in an athletics meeting held at the Tokyo Navy Dormitory in 1874, where the main event was a short-distance sprint. Therefore, ALPE is a particularly important disorder in Japan.

4 Reason why Patients with Renal Hypouricemia Frequently Develop ALPE, and its Mechanism

4.1 Reason

It remains to be clarified why patients with renal hypouricemia frequently develop acute renal failure. The following hypothesis has been proposed. Oxidative stress is essential for the onset of ischemic acute renal failure. In the kidney, uric acid acts as a protective mechanism against oxidative stress. However, in patients with renal hypouricemia, a decrease in uric acid may allow exposure of the kidney to oxidative stress, causing ALPE [152,153].

4.2 Mechanism

The mechanism by which these patients develop ALPE also remains to be clarified. However, two hypotheses have been put forward, and active oxygen/renovascular spasm or tubular obstruction may be involved. One hypothesis is that patients with renal hypouricemia are exposed to active oxygen because the level of an active oxygen
scavenger, uric acid, is reduced. Therefore, exercise may increase active oxygen, causing spasm of the interlobar/arcuate arteries. Furthermore, blood reperfusion may promote the production of active oxygen, causing ALPE. Recently, Perlstein et al. [154] reported that hyperuricemia inhibited angiotensin-related renovascular constriction. Therefore, anaerobic exercise may enhance angiotensin-related renovascular constriction in the presence of renal hypouricemia, causing patchy renal ischemia.

The other hypothesis is related to the fact that the reabsorption of uric acid is impaired in patients with renal hypouricemia. Even when exercise increases the serum uric acid level, uric acid is not reabsorbed, thus gradually increasing the tubular level of uric acid. In addition, exercise-related dehydration and urine acidification may result in tubular occlusion via the crystallization of uric acid, causing ALPE. The tubular events may be similar to the pathogenesis of acute uric acid nephropathy. Yeun and Hasbargen [59] supported this hypothesis. However, it remains controversial whether ALPE is associated with tubular obstruction due to uric acid crystals. The data do not support this hypothesis. Previously published case reports have shown the following findings. (1) Uric acid crystals were detected in the urinary sediment in the initial phase in only 3 of 76 patients with ALPE. (2) The histological findings within the first 10 days after onset in 9 of 28 patients who underwent kidney biopsy (mean interval from onset until kidney biopsy 11 ± 8 days) did not suggest acute uric acid nephropathy. However, there was no information on alcohol fixation for detecting uric acid crystals. (3) Patients with acute uric acid nephropathy are reported to show a UUA/Ucr value of 1.0 or more. However, the mean UUA/Ucr ratio was approximately 0.4 in our series (including patients without renal hypouricemia). (4) In our exercise load test, the glomerular filtration rate reduced after exercise in patients with a history of ALPE, and then FEUA increased (as described below). (5) In patients with severe ALPE requiring dialysis, wedge-shaped contrast enhancement was also observed in the recovery phase. (6) It is difficult to explain loin pain and wedge-shaped contrast enhancement by the hypothesis involving tubular occlusion.

In conclusion, intrarenal topical circulatory disorder or vascular spasm may develop in patients with renal hypouricemia, leading to acute renal failure.
1 URAT1 Gene Analysis in Patients with Renal Hypouricemia who Developed ALPE

In 7 patients with renal hypouricemia who developed exercise-induced acute renal failure (ALPE), gene analysis was performed to investigate URAT1 mutation [117,126,149,155] (Table 10, Cases 1–7). The W258X homozygote, W258X heterozygote, and W258X/Q297X compound heterozygote were detected in 5, 1, and 1 patients, respectively.

We encountered a father (Patient 18) and his son (Patient 21) with renal hypouricemia who both developed ALPE (Table 10, Cases 8 and 9). The W258X homozygote was not detected in either patient. The father showed the R90H homozygote, and his son showed the R90H/W258X compound heterozygote. The details of these two patients are given below [36] (Fig. 57).

Patient 18: a 41-year-old man (father, Patient 1 in Fig. 57)

On June 6, this patient developed severe loin pain after he participated in two 150-m sprints at a town athletics meeting. After 5 days, he was referred to the outpatient clinic of our department. His serum creatinine and uric acid levels and FEUA, were 2.9 mg/dl, 2.1 mg/dl, and 49.7%, respectively. His creatine phosphokinase (CPK) level was normal. When his serum creatinine level decreased to 1.58 mg/dl, a contrast medium was administered. A delayed computed tomography (CT) scan after 24 and 48 h confirmed patchy wedge-shaped contrast enhancement (Fig. 58). Under a diagnosis of ALPE, his body water balance (hydration) was controlled. In this patient, recovery was achieved 4 weeks after onset, and his serum creatinine and uric acid levels were then 1.0 mg/dl and 0.6 mg/dl, respectively. Furthermore, load tests with a uric acid reabsorption inhibitor (benzbromarone) and a uric acid excretion inhibitor (pyrazinamide) suggested presecretory reabsorption defect-related renal hypouricemia. A kidney biopsy 16 days after onset confirmed the recovery from acute tubular necrosis.

Patient 21: a 14-year-old boy (son, Patient 2 in Fig. 57)

This patient developed severe loin pain 3 h after he participated in two 400-m races, a mock cavalry battle, and a tug of war at an athletics meeting, and he attended a
Table 10. URAT1 (SLC22A12) mutation in patients with renal hypouricemia who developed ALPE

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Exercise</th>
<th>Loin pain</th>
<th>Serum uric acid (after recovery)</th>
<th>FEUA</th>
<th>URAT1 mutation</th>
<th>Literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>M</td>
<td>Exercise</td>
<td>No description</td>
<td>4.3 μg/ml</td>
<td>95%</td>
<td>W258X homozygote</td>
<td>Enomoto 2002</td>
</tr>
<tr>
<td>2</td>
<td>45</td>
<td>M</td>
<td>Strenuous exercise</td>
<td>Abdominal pain</td>
<td>0.8 mg/dl</td>
<td>46%</td>
<td>W258X homozygote</td>
<td>Tanaka 2003</td>
</tr>
<tr>
<td>3</td>
<td>42</td>
<td>M</td>
<td>Strenuous exercise</td>
<td>Back pain</td>
<td>1.0 mg/dl</td>
<td>65.7%</td>
<td>W258X homozygote</td>
<td>Tanaka 2003</td>
</tr>
<tr>
<td>4</td>
<td>No description</td>
<td>M</td>
<td>Exercise</td>
<td>No description</td>
<td>1.0 mg/dl</td>
<td>85.1%</td>
<td>W258X homozygote</td>
<td>Ichida 2004</td>
</tr>
<tr>
<td>5</td>
<td>No description</td>
<td>M</td>
<td>Exercise</td>
<td>No description</td>
<td>0.7 mg/dl</td>
<td>47.9%</td>
<td>W258X/Q297X compound heterozygote</td>
<td>Ichida 2004</td>
</tr>
<tr>
<td>6</td>
<td>No description</td>
<td>M</td>
<td>Exercise</td>
<td>No description</td>
<td>0.6 mg/dl</td>
<td>97.1%</td>
<td>W258X homozygote</td>
<td>Ichida 2004</td>
</tr>
<tr>
<td>7</td>
<td>18</td>
<td>M</td>
<td>Strenuous exercise</td>
<td>Loin pain</td>
<td>0.9 mg/dl</td>
<td>50.1%</td>
<td>W258X homozygote</td>
<td>Nagaba 2004</td>
</tr>
<tr>
<td>8</td>
<td>41</td>
<td>M</td>
<td>150-m track race</td>
<td>Loin pain</td>
<td>0.6 mg/dl</td>
<td>67.0%</td>
<td>R90H homozygote</td>
<td>Ishikawa 2005</td>
</tr>
<tr>
<td>9</td>
<td>14</td>
<td>M</td>
<td>400-m track race</td>
<td>Loin pain</td>
<td>0.7 mg/dl</td>
<td>50.7%</td>
<td>R90H/W258X compound heterozygote</td>
<td>Ishikawa 2005</td>
</tr>
</tbody>
</table>

Fig. 57. Family tree of patients with renal hypouricemia who developed ALPE, and URAT1 (SLC22A12) gene analysis (From [36], with permission)
local clinic. This occurred 5 years after his father had developed ALPE. His serum creatinine and CPK levels were 1.45 mg/dl and 428 U/l (reference value 44–212 U/l), respectively. Under a diagnosis of muscular pain, a nonsteroidal anti-inflammatory drug (NSAID) was administered orally. However, after 3 days, he attended our hospital for loin pain and oliguria. His serum creatinine and uric acid levels were then 11.3 mg/dl and 7.4 mg/dl, respectively, and his FEUA was 65.7%, suggesting ALPE. This patient required 6 sessions of hemodialysis because of oliguria. After 4 weeks, both his serum creatinine and uric acid levels returned to 1.0 mg/dl. In the recovery phase, 40 ml contrast medium (iohexol) was administered. A delayed CT scan after 24 h (serum creatinine 3.8 mg/dl, Fig. 59) revealed multiple wedge-shaped contrast-enhanced areas. Furthermore, magnetic resonance imaging (MRI) 3 min after the administration of gadolinium–diethylenetriaminopentaoacetic acid (Gd–DTPA) (serum creatinine 1.54 mg/dl) showed an inversion of the delayed CT findings described above (Fig. 59) and less marked wedge-shaped low signal intensity. In this patient, the effects of benz bromarone and pyrazinamide suggested renal hypouricemia related to presecretory reabsorption defect.

We analyzed the SLC22A12 uric acid transport gene (URAT1) in 4 members of his family. After informed consent was obtained, a DNA sequence analysis for URAT1 was determined (Fig. 60). We examined the SLC22A12 exon and exon/
Fig. 59. Wedge-shaped contrast enhancement in Case 2 with ALPE in Fig. 57. a, MRI 3 min after the administration of Gd–DTPA (TR 120, TE 4.1/1). b, Delayed CT 24 h after the administration of contrast medium. These pictures are mirror images, as indicated by the arrows (From [36], with permission).

Fig. 60. Analysis of R90H (G269A) and W258X (G774A) by direct DNA sequencing in a family with renal hypouricemia
intron border areas using genomic DNA. As shown in Fig. 57, this patient’s father had the R90H homozygote, and the patient had the R90H/W258X compound heterozygote. The patient’s mother had the W258X heterozygote, showing a normal serum uric acid level. Her daughter had the R90H/W258X compound heterozygote involved in renal hypouricemia [36]. However, she did not have a history of ALPE.
Chapter 11
Risk Factors Other than Renal Hypouricemia

1 Exercise in the Presence of a Cold

At the onset of exercise-induced acute renal failure (ALPE), a slight fever was often observed, and most patients were positive for C-reactive protein (CRP). After considering the possibility of viral infection-associated ALPE, we investigated changes in the titers of various virus antibodies at onset and in the recovery phase. However, there were no significant changes.

2 Administration of Antipyretic Analgesics Before Exercise

In 34% of patients, anaerobic exercise after taking analgesic agents for a cold induced ALPE. The oral administration of nonsteroidal anti-inflammatory drugs (NSAIDs) may be a risk factor.

3 Exercise in the Presence of Dehydration

Dehydration is a risk factor for all types of acute renal failure. It promotes the onset of ALPE, but may not be an important factor. The significance of dehydration in the pathogenesis of ALPE remains to be clarified.
Chapter 12
Etiology/Pathogenesis

1 Hypothesis About the Development of Exercise-Induced Acute Renal Failure (ALPE)

The pathogenesis of ALPE remains to be clarified. However, we propose the following hypothesis [4] (Fig. 61). Initially, anaerobic exercise such as a sprint may cause anaerobic glycolysis disorder of type II muscle fibers. Subsequently, adenosine 5′-triphosphate (ATP) deficiency may result in muscular injury. As a result, renal vasoconstrictive factors other than myoglobin may be released, promoting renovascular spasm at the interlobar/arcuate artery levels. However, for some reason, the grade of spasm may differ from branch to branch. The vascular spasm may induce acute tubular necrosis without increases in creatine phosphokinase (CPK) and serum myoglobin on the one hand, and renal angina with loin pain on the other. Risk factors for ALPE include renal hypouricemia, analgesic agents, and dehydration. However, vasoconstrictive factors remain to be clarified, and the involvement of muscle-derived substances and active oxygen is assumed. Furthermore, it is unclear why the grade of vascular spasm differs among the renal arterial branches, and at present there is no hypothesis to explain this.

2 Investigation of Serum-Specific Markers (SDS–PAGE, Proteomics)

In order to clarify the vasoconstrictive factors, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was carried out in the initial phase of our study. In the patients with myoglobinuric acute renal failure, myoglobin bands were detected. However, there were no ALPE-specific bands (Fig. 62).

We carried out proteomic analysis using a surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI–TOF–MS) and ProteinChips, which facilitate the analysis of low molecular weight proteins (Ishikawa, unpublished results, 2005). In the ALPE group, 18 marker candidates were found (molecular weight 3.5 KDa/4.3 KDa (Fig. 63)) in whom the relative intensity was higher than in the myoglobinuric acute renal failure and normal groups. We performed hierarchical clustering analysis by combining these marker candidates. In the ALPE group, the pattern differed from those in the myoglobinuric acute renal failure and normal groups (Fig. 64). However, no ALPE-specific single biomarker was found.
Fig. 61. Pathogenesis of ALPE (hypothesis)

Fig. 62. SDS–PAGE in normal controls and in patients with myoglobinuric acute renal failure, ALPE, or acute renal failure related to other etiologies. There were no bands which were specific to ALPE. ARF, acute renal failure
Fig. 63. Single marker analysis with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI–TOF–MS) in the ALPE, myoglobinuric acute renal failure, and normal groups. In the ALPE group, the relative intensity of a 3.5 KDa/4.3 KDa peptide was higher than that in the other groups.

Fig. 64. Proteomic analysis with a SELDI–TOF–MS. In single marker analysis (left), the relative intensity of the 3.5 KDa peptide was high in the ALPE group. In the hierarchical clustering analysis with marker candidates, the heat map in the ALPE group differed from those in the myoglobinuric acute renal failure and normal groups.
If several candidates are purified and identified in the future, some ALPE-specific markers may be found. However, the pathogenesis of patchy renovascular spasm may involve several factors, not just a single factor.

3 Investigation of Oxidative Stress Markers

Oxidative stress plays an important role in the onset of ischemic acute renal failure [156,157]. However, it is unclear whether oxidative stress is involved in the onset of ALPE. To investigate changes in oxidative stress, markers such as 8-isoprostane and NOx are used. In particular, 8-isoprostane is produced by prostaglandin in the presence of oxidative stress, and is considered to be a useful marker [158]. We measured 8-isoprostane as a marker, and investigated changes in oxidative stress using urine samples from patients with ALPE. In these patients, there was no increase in urinary 8-isoprostane even when their serum creatinine level was high. In the recovery phase, there was a transient increase (Fig. 65); there was no increase in oxidative stress, and the involvement of oxidative stress in the pathogenesis of ALPE has not been demonstrated.

4 Exercise Load Tests

Test 1

We enrolled five members of the Kanazawa Medical University Soccer Team (including one member with a history of ALPE) in order to examine changes in serum creatinine, serum myoglobin, and CPK before and after a match. There were no differences in the levels of change in these three parameters regardless of the presence or absence of a history of ALPE (Fig. 66). We did not investigate creatinine clearance.

![Fig. 65. Relationship between urinary 8-isoprostane and serum creatinine levels. In the initial phase, when the serum creatinine level was high, there was no increase in urinary 8-isoprostane. In the recovery phase, the urinary 8-isoprostane level increased](image-url)
We selected one renal hypouricemia patient with a history of ALPE and one healthy adult (control) without a history of ALPE, and measured creatinine clearance, FEUA, and oxidative stress markers (urinary 8-isoprostane and NO\textsubscript{x}) after anaerobic and aerobic exercise load tests (a 400-m race, 16 min on a treadmill, Bruce method, 13.5 metabolic equivalents (METs)) (Fig. 67). In the hypouricemia patient, (a) exercise reduced creatinine clearance (Fig. 68), (b) FEUA increased 5 h after the exercise load test (Fig. 69), (c) the urinary 8-isoprostane level increased slightly 6–25 h after the exercise load test, although there were no marked differences compared with the control values (Fig. 70), and (d) the urinary NO\textsubscript{x} level increased 2 and 5 h after the exercise load test (Fig. 71). Thus, we found that exercise reduced creatinine clearance in the renal hypouricemia patient with a history of ALPE, but there was no marked influence of oxidative stress.

**Fig. 66.** Changes in CPK, serum myoglobin, and serum creatinine in the university soccer team members (including one member with a history of ALPE) before and after a soccer game. The increase in serum creatinine in the patient with a history of ALPE was not marked.

**Fig. 67.** Exercise load protocol. An anaerobic exercise load test was performed first, followed by an aerobic exercise load test.
Exercise-Induced Acute Renal Failure

**Fig. 68.** Exercise loading and creatinine clearance. In the exercise loading protocol described in Fig. 67, creatinine clearance after anaerobic exercise was reduced in a patient with a history of ALPE.

**Fig. 69.** Exercise loading and FEUA. In a patient with a history of ALPE, FEUA was reduced after exercise, but increased again 7–25 h later.

**Fig. 70.** Exercise loading and urinary 8-isoprostane levels. There were no marked differences in the changes in urinary 8-isoprostane between a patient with a history of ALPE and the control.

**Fig. 71.** Exercise loading and levels of urinary stable metabolites of NO (NOx). The changes in urinary NOx after exercise differed between a patient with a history of ALPE and the control.
5 Preparation of Wedge-Shaped Patchy Renal Ischemia in an Animal Experiment

To prepare an ALPE model, rats were made to exercise in a cistern after the administration of a nonsteroidal anti-inflammatory drug (NSAID). However, ALPE did not develop. To obtain wedge-shaped contrast enhancement in rats, various vasoactive agents were employed. After the administration of endothelin, angiotensin, or epinephrine, only diffuse contrast enhancement was achieved. However, after the administration of vasopressin at 50 U/kg (a dose for achieving hemostasis for esophageal varices in humans), patchy wedge-shaped contrast enhancement was achieved [159] (Fig. 72). Vasoactive agents such as vasopressin may be involved in renovascular spasm.

6 Verification of Hypotheses

6.1 Does ALPE develop via the release of a renal vasoconstricting substance by type II muscle fibers?

Some studies have suggested that a vasoconstrictive substance other than myoglobin is released by muscles in the presence of rhabdomyolysis [160,161], although no vasoconstrictive substance has been identified by analysis with a SELDI–TOF–MS. However, patients with renal hypouricemia may be sensitive to vasoactive substances (such as angiotensin), and develop vascular spasm rather frequently. In an animal experiment, imaging after the administration of vasopressin showed patchy wedge-shaped contrast enhancement in the kidney. In addition, in some patients with ALPE, ischemia was observed not only in the kidney but also in other organs, suggesting concurrent vascular spasm in the intestinal tract, liver [43], and brain (cerebral infarction) [69]. These findings suggest that vasoconstrictive factors are involved in the onset of ALPE. However, the details remain to be clarified.
6.2 *Involvement of active oxygen and various vasoactive substances*

Exercise increases the levels of active oxygen and vasoactive substances such as endothelin, vasopressin, and catecholamines, and reduces the level of nitric oxide (NO). In this study, we investigated whether active oxygen is involved in the pathogenesis of ALPE. However, the results of measurements of 8-isoprostan and NOx did not suggest the involvement of active oxygen. Many patients with ALPE showed slight fever and an increase in C-reactive protein (CRP), although the association of these findings with the disorder was unclear. This suggests the involvement of inflammation and cytokines in the onset of ALPE. However, viral infection is ruled out. All possible mechanisms should be thoroughly investigated.

6.3 *Why does vascular spasm persist for a long period?*

We speculate that ischemia induces changes in the tubulo-interstitium by such factors as oxidative stress, apoptosis, an increase in intracellular Ca, complement activation, ICAM-1 expression, and inflammation, in a region controlled by the blood vessels, thereby influencing the blood vessels and prolonging vascular spasm. Coronary spasm persists for 15 min, and cerebrovascular spasm in the presence of subarachnoid hemorrhage persists for a week in some patients. Therefore, renovascular spasm may persist for a long period.
Chapter 13
Diagnosis

1 Initially Suspected Disorders
At the Emergency Outpatient Unit, most patients were initially diagnosed as having ureteral stone, or acute gastroenteritis based on vomiting/slight fever, or acute pancreatitis, lumbar pain, muscular pain, or lumbar disc hernia based on severe pain (Fig. 73).

2 Diagnosis of ALPE
In patients complaining of severe loin pain and nausea/vomiting after a sprint in an athletics meeting, a differential diagnosis of exercise-induced acute renal failure (ALPE) should be suggested, considering the risk of ALPE. In particular, this disorder must be considered first in patients with a history of ALPE. In the presence of ALPE, the serum creatinine level increases slightly a few hours after onset. However, neither myoglobinuria nor creatine phosphokinase (CPK) elevation is noted, which is different from what is usually found with rhabdomyolysis. When the serum uric acid level is normal or below the normal range despite an increase in the serum creatinine level, ALPE complicated by renal hypouricemia should be considered. In particular, this disorder may frequently recur when familial renal hypouricemia or a history of post-exercise loin pain is present.

3 Differentiation of ALPE from Myoglobinuric Acute Renal Failure
We compared ALPE (non-myoglobinuric acute renal failure) with myoglobinuric acute renal failure (Table 11).
ALPE frequently developed after anaerobic exercise, and caused severe loin pain, nausea/vomiting, and slight fever without dark urine. Furthermore, the serum myoglobin and CPK levels were normal or slightly increased, and delayed computed tomography (CT) showed wedge-shaped contrast enhancement.
Exercise-Induced Acute Renal Failure

Fig. 73. Disorders suspected on the first visit to an outpatient department (in patients for whom the disorder was described)

Table 11. Differential diagnosis of exercise-induced acute renal failure (ALPE) from myoglobinuric acute renal failure

<table>
<thead>
<tr>
<th></th>
<th>Exercise-induced acute renal failure (ALPE)</th>
<th>Myoglobinuric acute renal failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extent of exercise</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Type of exercise</td>
<td>Anaerobic (track race, swimming)</td>
<td>Aerobic (marathon, mountain climbing)</td>
</tr>
<tr>
<td>Urine volume</td>
<td>Nonoliguric</td>
<td>Oliguric</td>
</tr>
<tr>
<td>Dark urine</td>
<td>−</td>
<td>+++</td>
</tr>
<tr>
<td>Loin pain</td>
<td>+++</td>
<td>− − +</td>
</tr>
<tr>
<td>Nausea, vomiting, slight fever</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Dehydration</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Serum myoglobin, CPK</td>
<td>Normal or slightly increased</td>
<td>++</td>
</tr>
<tr>
<td>Delayed CT scan after administration of contrast medium</td>
<td>Patchy wedge-shaped enhancement</td>
<td>Diffuse enhancement</td>
</tr>
</tbody>
</table>


Diagnosis

Myoglobinuric acute renal failure developed after continued strenuous exercise. Marked muscular destruction (rhabdomyolysis) resulted in dark urine. However, there was no pain, and dehydration was marked. The CPK level showed a 10- to 20-fold increase compared with the reference value. Delayed CT showed diffuse contrast enhancement (Fig. 74).

In the patients with ALPE, bone scans showed no muscular uptake of methylene diphosphonate (MDP). However, upper/lower limb muscle uptake of MDP was found in the patients with myoglobinuric acute renal failure (Fig. 75).

As shown in Fig. 76, exercise-related acute renal failure is classified into two types: myoglobinuric acute renal failure and non-myoglobinuric acute renal failure. The latter is represented by ALPE. The grade of rhabdomyolysis and the type/grade of muscle fibers affected are shown in Fig. 76. Pathogenetic factors for ALPE should be investigated in the future.
Fig. 75. Bone scan with MDP. In a patient with ALPE (left), there was no muscular uptake of MDP. However, muscular accumulation of MDP (arrows) was observed in a patient with myoglobinuric acute renal failure (right). In the ALPE patient, it was impossible to evaluate the presence or absence of patchy accumulation in the kidney.

Fig. 76. Comparison of the pathogenesis between myoglobinuric acute renal failure and non-myoglobinuric acute renal failure represented by ALPE (hypothesis)
4 Necessity of Visualizing Wedge-Shaped Patchy Renal Ischemia

In the patients with ALPE, plain CT of the kidney (delayed CT) a few hours, 24 h, and 48 h after the administration of 40 ml contrast medium showed wedge-shaped contrast enhancement. When physicians hesitate to administer a contrast medium, patchy accumulation can be sometimes detected by magnetic resonance imaging (MRI) with gadolinium–diethylenetriaminopentaacetic acid (Gd–DTPA), bone scan with MDP, or ultrasonography with Levovist.

In addition to ALPE, mild acute renal failure, including dehydration, acute pyelonephritis, and renal pelvic tumors, is visualized as wedge-shaped contrast enhancement [15]. However, acute pyelonephritis and renal pelvic tumors are visualized as unilateral lesions, whereas ALPE is visualized as a bilateral lesion; therefore, differentiation is possible. For a definitive diagnosis, the presence of patchy contrast enhancement must be demonstrated when the serum creatinine level is in the range from 1.2 to 3.5 mg/dl. However, as described above, a definitive diagnosis is not always necessary in clinical practice.
Chapter 14
Treatment

1 Treatment

Treatment should be selected based on the grade of kidney dysfunction. In deciding on conservative therapy, hydration must be controlled. Hydration is normalized according to the presence or absence of overhydration and dehydration, although dehydration is rare. When oliguria, hyperpotassemia, and uremia are observed (21% of the patients), dialysis therapy should be considered according to the indication for dialysis therapy in acute tubular necrosis.

2 Precautions

As nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate ALPE, the administration of NSAIDs should be avoided even after onset. When patients require analgesic agents, synthetic opioid agonist/antagonist analgesics (pentazocine hydrochloride or buprenorphine hydrochloride) should be administered.
Chapter 15
Disease Course and Prognosis

1 Interval Required Until Improvement in Kidney Function

In our experience, the mean interval until the normalization of serum creatinine was 3 weeks.

2 Prognosis: Patients Undergoing Hemodialysis

This disorder shows a good prognosis, involving spontaneous recovery in most patients [4]. However, 29 (21.0%) of 138 patients required dialysis therapy owing to severe acute renal failure. No patient died in our series or in the literature consulted.
Chapter 16
Prevention

1 Preventive Methods

Methods of preventing exercise-induced acute renal failure (ALPE) and relapse have not been established as the etiology and pathogenesis of ALPE remain to be clarified. However, the following points are important.

1. Sprinting in an athletics meeting should be avoided if the athlete has a cold.
2. Nonsteroidal anti-inflammatory drugs (NSAIDs) should not be taken before exercise.
3. Exercise should be avoided in conditions of high temperature or humidity, and suitable preparatory exercise must be performed.
4. Repeated anaerobic exercise should be avoided.
5. The prevention of dehydration is essential (water supplementation, no exercise after drinking alcohol).
6. ALPE frequently develops and recurs in patients with renal hypouricemia, and caution is needed. When a relapse is suspected, patients should immediately consult a hospital without taking analgesic agents (NSAIDs). In particular, caution is needed when the patient’s base-line serum uric acid level is 1.0 mg/dl or less.

Some investigators have recommended that antioxidants (allopurinol, vitamin C, vitamin E) are taken for 5 days prior to exercise in order to prevent ALPE. However, their effects are unclear.

2 Precautions for Elementary and Junior/Senior High Schools

If a renal hypouricemia patient with a serum uric acid level of 1.0 mg/dl or less wishes to join an athletics sports team (short track sprint) at school, a physician should instruct them to change to other activities. If a patient participates in a track event at an athletics meeting, a physician should instruct them to comply with the preventive methods described above.
1. Exercise-induced acute renal failure (ALPE) frequently develops in young healthy males after repeated anaerobic exercise such as a 200-m race. The recurrence rate is high.

2. The risk of ALPE is high in patients with renal hypouricemia, and in those who have a cold and take antipyretic analgesics before exercise.

3. Severe loin pain persists for 5 days (mean). Because of the pain, patients are often misdiagnosed as having ureteral stone.

4. Plain computed tomography (CT) after the administration of contrast medium (delayed CT) shows wedge-shaped contrast enhancement in the bilateral kidneys, which persists for 1–3 days.

5. Many patients have non-oliguric acute renal failure, with a good prognosis. However, some patients require dialysis. For treatment, hydration must be controlled, and nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided if possible. When oliguria is observed, dialysis therapy should be performed, as described for acute tubular necrosis.

ALPE is different from exertional rhabdomyolysis (myoglobinuric acute renal failure).

Diagnosis and treatment should be performed with reference to the findings described above.
Postscript

We have reviewed the cases of patients with exercise-induced acute renal failure (ALPE) who we have encountered since 1979, when we treated the first patient in our series.

We are able to identify the presence of this disorder, and summarize the diagnosis and treatment because (a) we had personal contact with the patients, (b) we had previous knowledge of the hemodynamics of acute renal failure, (c) we had been carrying out animal experiments into glycerol-induced acute renal failure (myohemoglobinuric acute renal failure) for many years, and (d) a new diagnostic procedure, a computed tomography (CT) scan, had been developed and could be employed.

This disorder has gradually been recognized internationally during the past 26 years. It is quoted in the section on “Renal Hypouricemia” in UpToDate (electronic clinical reference on line). In Korea, several studies reported this disorder as patchy renal vasoconstriction [129]. Furthermore, the weekly magazine Shukan Bunshun (September 16, 2004) enlightened Japanese people about this disorder. On April 8, 2005, I gave a lecture entitled “Educational Lecture 9: Exercise-Induced Acute Renal Failure” at the 102nd general meeting of the Japanese Society of Internal Medicine [162].

The following issues, including the etiology, remain to be clarified: (a) the pathogenesis of ALPE, (b) the prevention of relapse, and future exercise guidance, (c) why delayed CT shows patchy contrast enhancement even in the recovery phase, (d) whether or not patchy renal vasoconstriction persists for 1–2 weeks, (e) why a contrast medium is present in the kidney for 72 h maximum, (f) the association between ALPE and disorders of type II muscle fibers, (g) the reasons for the less marked increases in serum myoglobin and creatine phosphokinase (CPK), and (h) why ALPE frequently develops in patients with renal hypouricemia.

These issues must be clarified in the future.
Acknowledgments

We thank the late Prof. Takeuchi, the late Dr. Berman, Prof. Hollenberg, the late Dr. Shinoda, staff in the Department of Nephrology, Kanazawa Medical University, and physicians in Keiju General Hospital and Asanogawa General Hospital for their cooperation.
Brief History of the Author

1965: Graduated from Kanazawa University School of Medicine.
1970: Completed a course in the Department of Medical Research, Kanazawa University Graduate School (First Department of Internal Medicine, instructed by Prof. Takeuchi), and obtained a doctorate of medicine (PhD).
1972–1973: Joined kidney disease study activities as a fellow at Mt. Sinai Hospital of Cleveland in the United States.
1973–1975: Studied under Prof. Hollenberg and Prof. Merrill at Peter Bent Brigham (the present Brigham and Women’s) Hospital (Boston) and the School of Medicine, Harvard University, in the United States.
1975: After returning to Japan, took office as an associate professor in the Department of Nephrology, Kanazawa Medical University.
April 1989: Took office as a professor in the Department of Nephrology, Kanazawa Medical University, and as a professor at the General Medical Research Institute.
September 1994: Took office as the chief professor in the Department of Nephrology, Kanazawa Medical University.
April 2004: After a departmental reorganization, took office as a professor in the Department of Kidney Function Therapeutics (Nephrology), Kanazawa Medical University.
March 2006: Retired at the normal retirement age.
April 2006: Emeritus Professor of Kanazawa Medical University and Department of Nephrology, Asanogawa General Hospital.
References

References


102 References


References

Index

abdominal pain 30, 36  
acetaminophen 28  
active oxygen 57, 58, 74  
active oxygen scavenger 57  
acute enteritis 33, 36  
acute gastroenteritis 75, 76  
acute interstitial nephritis 31  
acute kidney injury (AKI) 1  
acute pancreatitis 14, 76  
acute pyelonephritis 40, 79  
acute tubular necrosis 2, 3, 5, 41  
acute uric acid nephropathy 10, 58  
aerobic 76  
aerobic exercise 49  
age 56  
Alcian blue 3  
allopurinol 85  
ALPE 1, 2, 12, 13, 17, 35, 57, 59, 61  
ALPE model 73  
aminopropionic acid 7  
aminopyrine 3, 7  
an aerobic 76  
an aerobic exercise V, 21, 49, 57, 68, 71, 87  
analgesic ingestion 44  
angiotensin 73  
angiotensin-converting enzyme inhibitor 8  
animal experiment 73  
antioxidants 85  
antipyretic analgesics 43, 65  
aspirin 5, 28  
athletics meeting 3, 5, 18, 21, 22, 75  
ATP 51  
avtosomal dominant polycystic kidney disease (ADPKD) 33, 35  
background 43  
badminton 22, 40  
baseball 22, 33  
baseball game 38  
benzbromarone 29, 59, 61  
bilateral lesion 79  
bilateral loin pain 37  
biomarker 67  
bone scan 13, 41, 77  
bone scan with MDP 14, 31, 32, 78  
bucetin 5  
buprenorphine hydrochloride 81  
calculi in the urinary tract 76  
cerebrovascular spasm 54, 74  
cold 28, 35, 43, 65  
colic 29  
colicky pain 28  
computed tomography 3  
contrast medium 3  
coronary spasm 74  
cortex 11  
cortical enhancement 9  
cortical phase 77  
corticomedullary junction time 12  
corticopelvic junction time 12  
course 83  
C-reactive protein (CRP) 30, 40, 43  
creatinine phosphokinase (CPK) 1, 3, 17, 21, 25, 46  
creatinine clearance 72  
criteria 17  
CT attenuation value 11  
CT scan 3
dark urine 1, 24, 76
definition 17
dehydration 65, 76, 81
delayed CT 3, 6, 9, 32, 33, 39, 41, 62, 79, 87
diagnosis 75
dialysis therapy 45
diclofenac sodium 26
differential diagnosis 75
diffuse contrast enhancement 11
diffuse, patchy 23
drip infusion pyelography 5
drowning 22
dynamic CT 6, 9, 11

8-isoprostane 70
emergency care  V
emergency outpatient unit 3, 75
ethanzamide 28
etiology 67
excretory phase 77
exercise 17
exercise-induced acute renal failure (ALPE) 1, 17, 21, 43, 55
exercise load test 58, 70
exercise-related acute renal failure 1, 77
exertional rhabdomyolysis 1, 87

feature of pain 53
FENa 24, 34
FEUA 28, 29, 56, 72
fishing 37
flight in a light plane 31
flu-like symptoms 5
4-component model 55
400-m race 27, 38
gadolinium–diethylenetriaminopentaacetic acid (Gd–DTPA) 13, 61, 62
glomerular filtration rate 9, 11
glycerol-induced acute renal failure 89

heat stroke 1
hemodialysis 38, 83
hemoglobin 1
hemorrhagic fever with renal syndrome 54
heterozygote 63
hierarchical clustering analysis 67, 69
homozygote 63
hyperconcentration 9
hyperpotassemia 81
hypertension 43
hypothesis 67
hypouricemia 25
indication for dialysis therapy 81
indomethacin 30
inflammation 74
initial serum creatinine 56
intralobar/arcuate artery 9
intrarenal topical circulatory disorder 58
intravenous pyelography 3

Japan 57
kidney biopsy 3–5, 25, 41, 47, 58
kidney dysfunction 81
kidney hypofunction 5
knock pain 28
Korea 89
Leovist 13, 79
literature 55
loin pain 3, 17, 53, 87
loin pain hematuria syndrome 54
low-signal-intensity 27
lumbar disc hernia 53
lumbar pain 30
malignant syndrome 12
marathon 49
marathon running 1
maximum serum creatinine 45
MDP 13
MDP bone scan 15
medulla 11, 26
metabolic acidosis 33
microspheres 3
minimal change nephrotic syndrome 31
molecular weight 67
mountain climbing 1
MRI 13, 16, 26, 36, 37, 40, 41, 61, 79
muscular pain 38
myoglobin 1, 51
myoglobinuria 2, 25
myoglobinuric acute renal failure 1, 12, 13, 75, 77, 78
m/z 69
nausea/vomiting 44, 75
nephralgia 54
no renal hypouricemia 56
nocturnal hemoglobinuria 38
non-myoglobinuric acute renal failure 75, 78
non-oliguric acute renal failure 87
nontypical cases 19
normal kidney function 12
NSAID 38, 61, 73, 81, 87
oliguria 2, 13, 24, 81
100-m races 30
overhydration 43, 81
oxidative stress 57
oxidative stress markers 70
papillary region 9
patchy lesions 14, 36
patchy renal ischemia 57
patchy renal vasoconstriction 3, 89
patchy renovascular spasm 70
patchy wedge-shaped contrast enhancement 73
pathogenesis 67
pediatricians V
pentazocine hydrochloride 5, 7, 81
peptide 69
postsecretory reabsorption defect 56
presecretory reabsorption 29
presecretory reabsorption defect 61
presecretory reabsorption defect type 55
prevention 85
prodrome 44
prognosis 83
ProteinChips 67
proteomics 67
pyrazinamide 29, 59, 61
rat 4, 73
recurrence 47, 56
regional kidney function 9, 11
relapse 47
renal angina 54
renal artery stenosis 9
renal hypouricemia V, 21, 29, 36, 38, 44, 46, 55–57, 59, 65, 68, 87
renal infarction 3, 4, 11
renal ischemia 9
renal pelvic tumors 79
renal transport of uric acid 55
renal vasoconstriction 9
renovascular spasm 74
reperfusion 58
rhabdomyolysis 2, 14
risk factors 65
R90H 59, 60, 62
safety of contrast medium 13
scopolamine butylbromide 29
SDS–PAGE 67, 68
SELDI–TOF–MS 67, 69
serum creatinine 3, 11, 12, 56
serum myoglobin 21, 25, 46
short-distance sprint 18
short track 2, 50
single marker analysis 69
site of pain 53
skiing 22
SLC22A12 57, 60
slight fever 29, 56, 75
soccer 50, 71
sodium iothalamate 5
spasm of the interlobar/arcuate arteries 58
sports physicians V
sprinting 21, 49
strenuous exercise 1, 77
summary 45
swimming 22, 50
swimming race 5
time trial 22
timing of ALPE 50
treadmill 71
treatment 81
tubular obstruction 9–11, 57
200-m race 3
200-m sprint 17
type II muscle fibers 49, 51, 67, 68, 73
type of exercise 49, 50
type of muscle fiber 51
types of disordered renal uric acid transport 56

ultrasonography 13, 79
UNa 34
unaccustomed violent exercise 18
unilateral lesions 79
UOsm 34, 44
URAT1 gene analysis 59, 60
ureteral stone 3, 7, 30, 75
uric acid 55, 56
uric acid crystals 10, 58
uric acid transporter 1 (URAT1) 57, 60
urinalysis 29
urinary 8-isoprostane 71, 72
urinary NOx 71, 72
urinary sediment 28

urinary sodium 5
urolithiasis 18
UUA/Ucr 58
vascular spasm 58, 67
vascular spasm in the intestinal tract, liver, and brain 73
vascular spasm-related pain 54
vasoconstriction 3, 4
vasoconstrictive factors 73
vasopressin 73, 74
vitamin C 85
vitamin E 85

wedge-shaped contrast enhancement 4, 9, 10, 15–17, 44, 61
wedge-shaped lesions by CT scan 56
wedge-shaped patchy renal ischemia 3, 9, 46, 79
wedge-shaped renal lesions 11
weightlifting 26
white muscle 49
W258X 59, 60, 62

young healthy males 87